ueec_10q.htm

0001477932-23-005842.txt : 20230809 0001477932-23-005842.hdr.sgml : 20230809 20230809171010 ACCESSION NUMBER: 0001477932-23-005842 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: United Health Products, Inc. CENTRAL INDEX KEY: 0001096938 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 841517723 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27781 FILM NUMBER: 231156206 BUSINESS ADDRESS: STREET 1: 526 COMMERCE CIRCLE STREET 2: STE. #120 CITY: MESQUITE STATE: NV ZIP: 89027 BUSINESS PHONE: 475-755-1005 MAIL ADDRESS: STREET 1: 526 COMMERCE CIRCLE STREET 2: STE. #120 CITY: MESQUITE STATE: NV ZIP: 89027 FORMER COMPANY: FORMER CONFORMED NAME: United EcoEnergy Corp. DATE OF NAME CHANGE: 20060224 FORMER COMPANY: FORMER CONFORMED NAME: MNS EAGLE EQUITY GROUP III INC DATE OF NAME CHANGE: 19991019 10-Q 1 ueec_10q.htm FORM 10-Q ueec_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number: 000-27781

UNITED HEALTH PRODUCTS, INC.

(Exact name of Company as specified in its charter)

Nevada

84-1517723

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

526 Commerce Circle, Suite #120

Mesquite, NV

89027

(Address of Company’s principal executive offices)

(Zip Code)

(475) 755-1005

(Company’s telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12 (b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the 12 preceding months (or such shorter period that the registrant was required to submit such file). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares issued and outstanding of the Registrant’s Common Stock, as of August 9, 2023 was 241,123,222.

UNITED HEALTH PRODUCTS, INC.

FORM 10-Q QUARTERLY REPORT

TABLE OF CONTENTS

		PAGE
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)

	Condensed Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022	3

	Condensed Statements of Operations for the Three and Six Months Ended June 30, 2023 and June 30, 2022 (unaudited)	4

	Condensed Statement of Stockholders’ Deficiency for the Three and Six Months Ended June 30, 2023 and June 30, 2022 (unaudited)	5

	Condensed Statements of Cash Flows for the Six Months Ended June 30, 2023 and June 30, 2022 (unaudited)	7

	Notes to Condensed Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures	25

Item 4.	Controls and Procedures	25

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3.	Defaults Upon Senior Securities	26

Item 4.	Mine Safety Disclosures	26

Item 5.	Other Information	26

Item 6.	Exhibits and Reports on Form 8-K	27

SIGNATURES		29

Table of Contents

UNITED HEALTH PRODUCTS, INC.

Condensed Balance Sheets

	June 30,			December 31,
	2023			2022
	(Unaudited)
ASSETS
Current Assets
Cash and Cash Equivalents	$	133,601		$	13,377
Inventory		33,598			34,730
Prepaid and other current assets		7,563			22,932
Total current assets		174,762			71,039

Deferred offering costs		132,281			243,039
Operating lease right-of-use asset		89,575			-
Security deposit		2,850			-
Patents, net		34,425			36,450

TOTAL ASSETS	$	433,893		$	350,528

Current Liabilities
Accounts payable and accrued expenses	$	1,116,562		$	1,255,232
Accrued liabilities - related parties		174,040			172,579
Accrued litigation settlement		150,000			300,000
Operating lease liability - current		22,208			-
Promissory note payable		10,000			9,136
Loans payable – related parties		4,000			4,000
Convertible notes payable, net of debt discount		201,935			196,177
Convertible notes payable – related party, net of debt discount		490,221			478,331
Total current liabilities		2,168,966			2,415,455

Operating lease liability – long-term		67,367			-
TOTAL LIABILITIES		2,236,333			2,415,455

Commitments and Contingencies		-			-

Stockholders’ Deficit
Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding		-			-
Common Stock - $0.001 par value, 300,000,000 shares Authorized, 241,123,222 and 230,871,034 shares issued and outstanding at June 30, 2023 and December 31, 2022		241,123			230,871
Subscription Receivable		(311,820	)		(50,550	)
Additional Paid-In Capital		74,009,817			71,830,695
Accumulated Deficit		(75,741,560	)		(74,075,943	)
Total Stockholders’ Deficit		(1,802,440	)		(2,064,927	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	433,893		$	350,528

See notes to unaudited condensed financial statements.

Table of Contents

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Operations

(Unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2023			2022			2023			2022

Revenues	$	-		$	-		$	-		$	-
Operating Costs and Expenses
Selling, general and administrative expenses		370,343			607,186			1,205,642			1,509,332
Research and development		105,113			147,611			323,789			199,966
Total Operating Expenses		475,456			754,797			1,529,431			1,709,298

Loss from Operations		(475,456	)		(754,797	)		(1,529,431	)		(1,709,298	)

Other Income (Expenses)
Interest expense		(8,329	)		(205	)		(16,656	)		(285	)
Interest expense – related party		(19,532	)		(11,535	)		(38,998	)		(20,343	)
Loss on settlement of debt		(19,594	)		(112,500	)		(80,532	)		(113,375	)
Total other income (expenses)		(47,455	)		(124,240	)		(136,186	)		(134,003	)

Net Loss	$	(522,911	)	$	(879,037	)	$	(1,665,617	)	$	(1,843,301	)

Net Loss per common share:
Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)

Weighted average number of shares outstanding		238,269,719			229,737,399			235,376,226			229,257,932

See notes to unaudited condensed financial statements.

Table of Contents

UNITED HEALTH PRODUCTS, INC

Condensed Statement of Stockholders’ Deficiency

Three and Six Months Ended June 30, 2023 and June 30, 2022

(Unaudited)

							Additional
	Common Stock						Paid-in		Subscription		Accumulated
	Shares			Amount			Capital		Receivable		Deficit			Total

Balance at December 31, 2021		228,667,229		$	228,667		$	71,017,881	$	-	$	(72,388,442	)	$	(1,141,894	)

Issuance of common stock for services		20,000			20			10,180		-		-			10,200

Sale of common stock		184,028			184			77,108		-		-			77,292

Common stock issued to settle accounts payable and accrued liabilities		6,252			6			3,995		-		-			4,001

Net Loss		-			-					-		(964,264	)		(964,264	)

Balance at March 31, 2022		228,877,509			228,877			71,109,164	$	-		(73,352,706	)		(2,014,665	)

Issuance of common stock for services		200,000			200			95,800		-		-			96,000

Issuance of common stock for services – related party		425,000			425			203,575		-		-			204,000

Common stock issued to settle accounts payable and accrued liabilities		20,000			200			95,800		-		-			96,000

Common stock issued to settle accounts payable and accrued liabilities – related party		425,000			425			203,575		-		-			204,000

Cancellation of common stock		(250,000	)		(250	)		250		-		-			-

Net Loss		-			-			-		-		(879,037	)		(879,037	)

Balance at June 30, 2022		229,877,509		$	229,877		$	71,708,164	$	-	$	(74,231,743	)	$	(2,293,702	)

Table of Contents

					Additional
	Common Stock				Paid-in			Subscription			Accumulated
	Shares		Amount		Capital			Receivable			Deficit			Total

Balance at December 31, 2022		230,871,034	$	230,871	$	71,830,695		$	(50,550	)	$	(74,075,943	)	$	(2,064,927	)

Sale of common stock		2,535,000		2,535		522,770			50,550			-			575,855

Common stock issued to settle accrued liabilities – related party		637,500		638		168,300			-			-			168,938

Common stock issued to settle accrued liabilities		300,000		300		79,200			-			-			79,500

Common stock issued for a stock subscription receivable		400,000		400		71,317			(71,717	)		-			-

Amortization of deferred offering costs		-		-		(55,371	)		-			-			(55,371	)

Common stock issued for litigation settlement		1,850,000		1,850		460,650			-			-			462,500

Net Loss		-		-		-			-			(1,142,706	)		(1,142,706	)

Balance at March 31, 2023		236,593,534		236,594		73,077,561			(71,717	)		(75,218,649	)		(1,976,211	)

Sale of common stock		2,450,000		2,450		501,558			71,717			-			575,725

Common stock issued to settle accrued liabilities – related party		567,188		566		101,527			-			-			102,093

Common stock issued to settle accrued liabilities		412,500		413		73,838			-			-			74,251

Common stock issued for a stock subscription receivable		1,100,000		1,100		310,720			(311,820	)		-			-

Amortization of deferred offering costs		-		-		(55,387	)		-			-			(55,387	)

Net Loss		-		-		-			-			(522,911	)		(522,911	)

Balance at June 30, 2023		241,123,222	$	241,123	$	74,009,817		$	(311,820	)	$	(75,741,560	)	$	(1,802,440	)

See notes to unaudited condensed financial statements.

Table of Contents

UNITED HEALTH PRODUCTS, INC.

Condensed Statements of Cash Flows

(Unaudited)

	For the Six Months Ended June 30,
	2023			2022

Cash Flows from Operating Activities:
Net (Loss)	$	(1,665,617	)	$	(1,843,301	)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:
Stock for services and compensation		-			310,200
Amortization expense		2,025			2,025
Amortization of debt discount		17,648			-
Loss on settlement of debt		80,532			113,375
Stock issued for litigation settlement		462,500			-
Changes in assets and liabilities:
Inventory		1,132			-
Prepaid and other current assets		15,369			(9,206	)
Accounts payable and accrued expenses		(12,670	)		500,774
Accrued liabilities – related party		229,711			146,944
Accrued litigation settlement		(150,000	)		380,000
Net Cash Used In Operating Activities		(1,019,370	)		(399,189	)

Cash Flows from Investing Activities:
Purchase of intangible assets		-			(40,500	)
Security deposit		(2,850	)		-
Net Cash Used in Investing Activities		(2,850	)		(40,500	)

Cash Flows from Financing Activities:
Proceeds from related party		-			383,275
Repayments on loan payable		(9,136	)		(36,261	)
Proceeds from sale of common stock		1,151,580			77,292
Cash flow provided by financing activities		1,142,444			424,306
Increase (decrease) in Cash and Cash Equivalents		120,224			(15,383	)
Cash and Cash Equivalents – Beginning of period		13,377			21,799

CASH AND CASH EQUIVALENTS – END OF PERIOD	$	133,601		$	6,416

Supplemental cash flow information:
Cash paid for interest	$	15		$	285
Cash paid for income taxes	$	-		$	-

Non-cash Investing & Financing Activities:
Cancellation of common stock	$	-		$	250
Common stock issued for subscription receivable	$	311,820		$	-
Amortization of deferred offering costs	$	110,758		$	-
Initial recognition of operating lease right-of-use asset and operating lease liability	$	92,425		$	-
Common stock issued to settle accrued liabilities – related party	$	218,250		$	127,500
Accounts payable and accrued expenses paid with promissory note payable	$	10,000		$	-
Common stock issued to settle accrued liabilities	$	126,000		$	63,126
Accrued litigation settlement paid with loan payable	$	-		$	100,000

See notes to unaudited condensed financial statements.

Table of Contents

UNITED HEALTH PRODUCTS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE QUARTERS ENDED JUNE 30, 2023 AND 2022

(Unaudited)

Note 1. Organization and Basis of Preparation

United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. The Company in the process of seeking regulatory approval to sell our HemoStyp product line into the U.S. Class III and European Union CE Mark surgical markets.

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 28, 2023.

In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

Note 2. Significant Accounting Policies

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Cash and Cash Equivalents

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Table of Contents

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

Fair Value Measurements

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

Trade Accounts Receivable and Concentration Risk

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.

Table of Contents

There were no provisions for doubtful accounts recorded at June 30, 2023 and December 31, 2022. The Company recorded $0 in bad debt expense for the three and six month periods ended June 30, 2023 and 2022.

Inventory

Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of work-in process.

June 30,

2023

December 31,

2022

Finished goods

33,598

34,730

Total inventory

33,598

34,730

During the six months ended June 30, 2023 and 2022, the Company determined that $0 needed to be impaired and written-off. During the six months ended June 30, 2023, the Company used $1,132 of inventory as samples for its FDA testing and recorded it to research and development on the Statement of Operations.

Stock Based Compensation

The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Stock-based compensation expense for employees and non-employees is measured at the grant date fair value. Stock-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

Per Share Information

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three and six months ended June 30, 2023 and 2022 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive.

Table of Contents

The total potential common shares as of June 30, 2023 included 47,665,000 of restricted stock units, 3,552,376 shares for convertible notes payable – related parties and 1,406,300 shares for convertible notes payable. The total potential common shares as of June 30, 2022 included 30,915,000 of restricted stock units.

Patents

Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed.

Accumulated amortization as of June 30, 2023 and December 31, 2022 was $6,075 and $4,050, respectively. Amortization expense for the six months ended June 30, 2023 and 2022 was $2,025, respectively.

Future Amortization Expense

Year	Amount
2023 (remaining)	$	2,025
2024		4,050
2025		4,050
2026		4,050
2027		4,050
Thereafter		16,200
	$	34,425

Impairment of Long-lived Assets

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended June 30, 2023 and 2022, the Company determined no impairment was required.

Deferred Offering Costs

Deferred offering costs represent specific incremental costs directly attributable to the offering of securities. The deferred offering costs are recorded as an offset to additional paid-in capital and charged against the proceeds received.

Advertising and Marketing Costs

Advertising and marketing expenses are expensed as incurred. The Company incurred $57,536 and $55,000 in advertising and marketing costs during the six months ended June 30, 2023 and 2022, respectively.

Research and Development

The Company charges research and development costs to expense when incurred. The Company incurred $323,789 and $199,966 in research and development expenses during the six months ended June 30, 2023 and 2022, respectively.

Leases

The Company follows the provisions of ASC 842, and records right-of-use ("ROU") assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments.

The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

New Accounting Pronouncements

The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Table of Contents

Note 3. Related Party Transactions

Convertible notes payable - related parties

During the year ended December 31, 2022, Brian Thom, the Company’s Chief Executive Officer, converted $372,000 of a loan payable balance to a convertible note payable. The unpaid accrued interest on the loan payable was transferred to the convertible note payable. The note has an interest rate of 10%, an original issue discount (“OID”) of 7% and has a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $28,000 of a debt discount related to the OID. As of June 30, 2023 and December 31, 2022, the remaining unamortized debt discount was $7,578 and $16,998, respectively. Accrued interest associated with the note was $55,592 and $33,897 as of June 30, 2023 and December 31, 2022, respectively.

During the year ended December 31, 2022, Robert Denser, a Director of the Company, loaned the Company $93,000 through a convertible note. The note has an interest rate of 10%, an OID of 7% and has a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $7,000 of a debt discount related to the OID. As of June 30, 2023 and December 31, 2022, the remaining unamortized debt discount was $2,201 and $4,671, respectively. Accrued interest associated with the note was $9,236 and $4,034 as of June 30, 2023 and December 31, 2022, respectively.

Interest expense – related party on the above convertible notes payable was $19,426 (including $5,978 of debt discount amortization related to the OID) and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $38,786 (including $11,890 of debt discount amortization related to the OID) and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest – related party due to these convertible notes was $64,828 and $37,931, as of June 30, 2023 and December 31, 2022, respectively.

Loans payable – related parties

During the year ended December 31, 2022, Kristofer Heaton, the Principal Financial Officer, loaned the Company $4,000 to pay for operating expenses. As of June 30, 2023 and December 31, 2022, $4,000 in principal was owed on the loan payable. The loan has an interest rate of 10% and is due on demand.

Interest expense – related party on the above loans was $106 and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $212 and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest – related party as of June 30, 2023 and December 31, 2022 was $436 and $224, respectively.

Accrued liabilities – related parties

As of June 30, 2023 and December 31, 2022, $108,776 and $127,500 of accrued compensation and reimbursable expenses was due to the Company’s officers and management, respectively.

Equity transactions

During the six months ended June 30, 2023, the Company issued 1,204,688 shares of common stock with a fair value of $271,031 to its officers and management for $218,250 of accrued compensation (see Note 6).

Table of Contents

Note 4. Promissory Note Payable

During the year ended December 31, 2022, the Company had entered into a $100,000 promissory note and had a principal balance of $9,136 and accrued interest of $0 as of December 31, 2022. The note accrued interest at 1% and requires monthly payments of $9,136 until the balance was paid in full.

During the six months ended June 30, 2023, the Company paid the remaining principal balance of $9,136. As of June 30, 2023, the principal balance and accrued interest was $0.

During the six months ended June 30, 2023, $10,000 of accounts payable and accrued liabilities were paid on behalf of the Company. The Company entered into a note payable for the $10,000 payment. The note payable has an interest rate of 5% and has a maturity date of December 31, 2023.

Interest expense on the above loans was $125 and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $250 and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest as of June 30, 2023 and December 31, 2022 was $250 and $0, respectively.

Note 5. Convertible Notes

During the year ended December 31, 2022, the Company issued a $93,000 convertible note and a $99,975 convertible note and received total proceeds of $192,975. The notes have an interest rate of 10%, an OID of 7% and have a maturity date of December 31, 2023. The notes are convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $14,525 of a debt discount related to the OID. As of June 30, 2023 and December 31, 2022, the remaining unamortized debt discount was $5,565 and $11,323, respectively.

Interest expense on the above convertible notes payable was $8,204 (including $2,895 of debt discount amortization related to the OID) and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $16,406 (including $5,758 of debt discount amortization related to the OID) and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest as of June 30, 2023 and December 31, 2022 was $16,102 and $5,454, respectively, and has been recorded in accrued liabilities on the balance sheet.

Note 6. Issuances of Securities

Share issuances 2022

During the six months ended June 30, 2022, the Company had the following common stock transactions:

	·	184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292.
	·	206,252 shares of commons stock with a fair value of $100,001 were issued to various consultants to settle $63,126 of accrued liabilities resulting in a loss on settlement of debt of $36,875.
	·	200,000 shares of common stock with a fair value of $96,000 were issued to consultants for services.
	·	425,000 shares of common stock were issued to settle $127,500 of accrued liabilities – related party resulting in a loss of settlement of debt of $76,500.
	·	425,000 shares of common stock with a fair value of $204,000 were issued to officers and a former officer of the Company for services.
	·	250,000 shares of common stock were cancelled reducing common stock by $250 and increasing additional paid-in capital by the same.
	·	20,000 shares of common stock with a fair value of $10,200 were issued for legal services.

Table of Contents

Share issuances 2023

During the six months ended June 30, 2023, the Company had the following common stock transactions:

	·	1,204,688 shares of common stock with a fair value of $271,031 were issued to officers and management of the Company to settle $218,250 of accrued liabilities (see Note 3) resulting in a loss on settlement of debt of $52,781.
	·	712,500 shares of common stock with a fair value of $153,751 were issued to consultants to settle $126,000 of accrued liabilities resulting in a loss on debt settlement of $27,751.
	·	5,385,000 shares of common stock were sold for $1,151,580, net of legal and administrative fees of $6,600 and which included a payment of $50,550 for a subscription receivable, under the Company’s common stock purchase agreement with White Lion. White Lion also purchased 1,100,000 shares for proceeds of $311,820 which were received in July 2023 and is shown as a subscription receivable in the balance sheet as of June 30, 2023.
	·	1,850,000 shares of common stock with a fair value of $462,500 were issued to settle litigation (see Note 8).

Restricted stock units

As of June 30, 2023 and December, 31, 2022, the Company has granted a total of 47,665,000 restricted stock units (RSU). The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones.

Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur and as of June 30, 2023, there was $25,313,630 of unrecognized compensation cost related to unvested restricted stock unit awards.

Table of Contents

Activity related to our restricted stock units during the three months ended June 30, 2023 was as follows:

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2022		47,665,000	$	0.54
Units granted		-	$	-
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at June 30, 2023		47,665,000	$	0.54

Note 7. Accrued Litigation Settlement

On June 15, 2022, the Security and Exchange Commission’s (SEC) investigation of the Company, initially reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, was settled through the filing of a consent judgment without the Company admitting or denying the SEC’s allegations. As part of the settlement, the Company is required to pay a civil penalty of $450,000, payable in four installments as follows:

	·	$50,000 upon the entry of the judgment;
	·	$100,000 within 90 days of the entry of the judgment;
	·	$150,000 within 180 days of the entry of the judgment; and
	·	$150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961

The Company has made total payments of $300,000 towards the civil penalty through June 30, 2023. As of June 30, 2023 and December 31, 2022, the remaining balance was $150,000 and $300,000, respectively. The Company and the SEC have agreed upon an amended schedule of payments for the remaining balance owed under the settlement (see Note 10).

Note 8. Litigation

Effective as of March 31, 2023, a 2018 lawsuit filed by Philip Forman, against the Company and its former CEO relating to the validity of a June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company and claims for compensation on termination of his employment was settled. In the settlement, as full and complete consideration, the Company issued to Mr. Forman 1,850,000 shares of common stock of the Company with a fair value of $462,500.

Table of Contents

Note 9. Leases

In May 2023, the Company entered into 36-month operating lease, which provides for approximately 1,800 square feet of office space, that commenced on June 1, 2023 and ends on May 31, 2026. The lease required a $2,850 security deposit and monthly lease payments are $2,850 the first year of the lease, $2,964 the second year and $3,082 the third year.

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. On the commencement date of the lease, the Company recorded $92,425 related to the ROU asset and lease liability.

The components of lease expense and supplemental cash flow information related to the lease for the period are as follows:

	Six Months Ended June 30, 2023
Lease Cost
Operating lease cost (included in general and administrative in the Company’s statement of operations)	$	2,850

Other Information
Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2023	$	2,850
Weighted average remaining lease term – operating leases (in years)	2.92 years
Average discount rate – operating lease		10	%

The supplemental balance sheet information related to leases for the period is as follows:

	At June 30, 2023		At December 31, 2022
Operating leases
Remaining right-of-use assets	$	89,575	$	-

Short-term operating lease liabilities	$	22,208	$	-
Long-term operating lease liabilities	$	67,367	$	-
Total operating lease liabilities	$	89,575	$	-

Maturities of the Company’s undiscounted lease liabilities are as follows:

Year Ending	Operating Leases
2023 (Remaining)	$	17,100
2024		34,998
2025		36,394
2026		15,410
Total lease payments		103,902
Less: Imputed interest/present value discount		(14,327	)
Present value of lease liabilities	$	89,575

Note 10. Subsequent Events

The Company has evaluated events from June 30, 2023, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed except as follows:

The Company has proposed an amended installment payment plan to the SEC related to its civil penalty (see Note 7). The proposed payment plan calls for the Company to make three $50,000 payments with payments due on August 1, 2023, September 1, 2023 and October 1, 2023 with any remaining principal plus outstanding post-judgement interest to be paid on November 1, 2023. The $50,000 due on August 1, 2023 was paid by the Company.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes appearing elsewhere in this quarterly report on Form 10-Q. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth under ‘Risk Factors’ in our annual report on Form 10-K for the fiscal year ended December 31, 2022, filed with SEC on March 28, 2023.

Company Overview

UHP develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp, is derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European CE Mark surgical markets.

Our HemoStyp Gauze Products

HemoStyp hemostatic gauze is a natural substance created from chemically treated cellulose derived from cotton. It is an effective hemostatic agent registered with the FDA for superficial use under a 510(k) approval obtained in 2012 to help control bleeding from open wounds and body cavities. The HemoStyp hemostatic material contains no chemical additives, thrombin, collagen or animal-derived products, and is hypoallergenic. When the product comes in contact with blood it expands slightly and quickly converts to a translucent gel that subsequently breaks down into glucose and salts. Because of its benign impact on body tissue and the fact that it degrades to non-toxic end products, HemoStyp does not impede the healing of body tissue as compared to certain competing hemostatic products. Laboratory testing has shown HemoStyp to be 100% absorbable in the human body within 24 hours, compared to days or weeks with competing organic regenerated cellulose products. A human trial conducted in 2019 and 2020 demonstrated the effectiveness of HemoStyp in vascular, thoracic and abdominal surgical procedures.

Table of Contents

HemoStyp hemostatic gauze is a flexible, silk-like material that is applied by placing the gauze onto the bleeding tissue. The supple material can be easily folded and manipulated as needed to fit the size of the wound or incision. In surface bleeding and surgical situations, the product quickly converts to a translucent gel that allows the physician or surgeon to monitor the coagulation process. The gel maintains a neutral pH level which avoids damaging the surrounding tissue. In superficial bleeding situations, HemoStyp can be bonded to an adhesive plastic bandage or integrated into a traditional gauze component to address a broad range of needs, including traumatic bleeding injuries and prolonged bleeding following hemodialysis.

Potential Target Markets

Our HemoStyp material is currently cut to several sizes and configuration and marketed as HemoStyp Gauze. While we have paused our commercial activities to focus on our Class III PMA application, our potential customer base includes, without limitation, the following:

	·	Hospitals and Surgery Centers for all Internal Surgical usage (in the event we obtain FDA Class III approval)
	·	Hospitals, Clinics and Physicians for external trauma
	·	EMS, Fire Departments and other First Responders
	·	Military Medical Care Providers
	·	Hemodialysis centers
	·	Nursing Homes and Assisted Living Facilities
	·	Dental and Oral & Maxillofacial Surgery Offices
	·	Veterinary hospitals

Primary Strategy

Our HemoStyp technology received an FDA 510(k) approval in 2012 for use in external or superficial bleeding situations and we believe there is an opportunity for HemoStyp products to address unmet needs in several medical applications that represent attractive commercial opportunities. However, the Class III surgical markets, both domestic and international, represent the most attractive market for our products due to the smaller number of competitors offering Class III approved hemostatic agents and the resulting premium pricing for products that can meet the demanding requirements of the human surgical environment. We believe that our extensive laboratory testing and our completed human trial indicate that the HemoStyp technology could successfully compete against established Class III market participants, and could gain a significant market share. There can be no assurance that an FDA Premarket Approval (PMA) will be granted.

In 2018, we made the decision to focus our efforts and resources on accessing these Class III markets to maximize the value potential of our HemoStyp products. The Class III PMA process required a substantial investment of time and resources so we made the strategic determination to deemphasize our sales and marketing to non-Class III markets in order to devote our full resources to the PMA process.

In anticipation of receiving a Class III PMA (which cannot be assured), we are evaluating paths to rapidly grow our revenue and profits in all potential market segments, with the objective of maximizing shareholder value. We do not intend to pursue the full commercialization of our products independently nor to remain an independent company in the long term. Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors, which may include a pre-sale collaboration on commercialization and distribution and (ii) one or more commercial partnerships with established market participants, without any specific, associated sale or merger transaction.

Table of Contents

The Company has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company’s products and business strategy. In response to these inbound contacts, we continue to engage in discussions to evaluate the potential commercial partnerships in anticipation of an FDA decision on our Class III PMA application. There can be no assurances that any specific transaction will occur as a result of these discussions. No assurances can be given that the Company will identify any commercialization candidate(s) or complete a transaction.

Manufacturing and Packaging of our Products

The Company’s products will be manufactured to our specifications through a contract manufacturing arrangement with an FDA certified supplier that maintains stringent quality control protocols to assure the uniformity and quality of all of our gauze products. Information on the manufacturing process and our manufacturer’s facility has been submitted as part of our PMA submission. Our gauze products are cut to size, packaged and sterilized by service providers in the United States.

Patents and Trademarks

Our hemostatic gauze technology is protected through patents granted by the U.S. Patent and Trademark Office, which protection currently runs through 2029. In 2020 and 2021, we filed additional U.S. and International patents that protect the use of our NORC technology in a gel or hydrocolloid formulation.

On January 21, 2021, the U.S. Patent Office provided notification of publication of the Company’s patent application for the method of forming and using a hemostatic hydrocolloid. This publication does not imply any assurance of the receipt of the patent but establishes an obligation of any party that seeks to use the applicable method to pay royalties for the right to do so. The patent application for this process remains pending as of the date of this filing.

On February 11, 2021, the Company was notified that its application to establish global patent protection for the process of creating and deploying a hydrocolloid (or gel) format of its HemoStyp technology was accepted for publication under the procedures of the Patent Cooperation Treaty (“PCT”), an international patent law treaty which provides a unified procedure for filing a patent application in most foreign countries. We previously filed provisional patent applications for our HemoStyp hydrocolloid process in 2020. In January 2022 the Company initiated steps to register its hydrocolloid patent in the European common market and in additional foreign countries where we intend to commercialize any future HemoStypo gel formats. We can give no assurance that foreign registration of our patents will be granted in any of these jurisdictions.

The Company has registered trademarks for the following product formats:

	·	Boo Boo Strips
	·	The Ultimate Bandage
	·	Hemostrips
	·	CelluSTAT
	·	Nik Fix

Table of Contents

Results of Operations for the three months ending June 30, 2023 and 2022

The following table sets forth a summary of certain key financial information for the three months ended June 30, 2023 and 2022:

	For the Three Months Ended June 30,
	2023			2022

Revenue	$	-		$	-

Gross profit	$	-		$	-

Operating (expenses)	$	(475,456	)	$	(754,797	)

Operating (loss)	$	(475,456	)	$	(754,797	)

Other income (expense)	$	(47,455	)	$	(124,240	)

Net (loss)	$	(522,911	)	$	(879,037	)

Net loss per common share - basic and diluted	$	(0.00	)	$	(0.00	)

Three Months ended June 30, 2023 versus Three Months ended June 30, 2022

During the three months ended June 30, 2023 and 2022, the Company had $0 of revenues. The Company did not generate any revenues due to the continued focus of the Company’s capital and resources towards obtaining a Class III PMA.

Total operating expenses for the three months ended June 30, 2023 and 2022 were $475,456 and $754,797, respectively.

The decrease in operating expenses was primarily due to the Company having issued 625,000 shares of common stock for services with a fair value of $300,000 during the three months ended June 30, 2022 compared to $0 during the three months ended June 30, 2023.

Other income (expense) for the three months ended June 30, 2023 and 2022 was $(47,455) and $(124,240), respectively. The decrease in other expense was due to a decrease in loss on settlement of debt of $92,906 offset by an increase in total interest expense of $16,121. The increase in interest expense was primarily due to the Company having a larger outstanding balance of interest bearing promissory notes along with $8,873 of debt discount amortization expense during the three months ended June 30, 2023 compared to $0 during the three months June 30, 2022.

The decrease in the loss on debt settlement was due to the Company issuing common stock with a fair value of $176,344 for the settlement of an aggregate of $156,750 of accrued liabilities and accrued liabilities – related parties resulting in loss on settlement of debt of $19,594 during the three months ended June 30, 2023 compared to the Company issuing common stock with a fair value of $300,000 for the settlement of an aggregate of $187,500 of accrued liabilities and accrued liabilities – related parties resulting in a loss on settlement of debt of $112,500 during the three months ended June 30, 2022.

Table of Contents

Our net loss for the three months ended June 30, 2023 was $522,911 as compared to net loss of $879,037 for the comparable period of the prior year. The decrease in the net loss is due to the Company having a decrease in operating expenses of $279,341 and a decrease in other expenses of $76,785, as explained above.

Results of Operations for the six months ending June 30, 2023 and 2022

The following table sets forth a summary of certain key financial information for the six months ended June 30, 2023 and 2022:

	For the Six Months Ended June 30,
	2023			2022

Revenue	$	-		$	-

Gross profit	$	-		$	-

Operating (expenses)	$	(1,529,431	)	$	(1,709,298	)

Operating (loss)	$	(1,529,431	)	$	(1,709,298	)

Other income (expense)	$	(136,186	)	$	(134,003	)

Net (loss)	$	(1,665,617	)	$	(1,843,301	)

Net loss per common share - basic and diluted	$	(0.01	)	$	(0.01	)

Six Months ended June 30, 2023 versus Six Months ended June 30, 2022

During the six months ended June 30, 2023 and 2022, the Company had $0 of revenues. The Company did not generate any revenues due to the continued focus of the Company’s capital and resources towards obtaining a Class III PMA.

Total operating expenses for the six months ended June 30, 2023 and 2022 were $1,529,431 and $1,709,298, respectively.

The decrease in operating expenses was due primarily to the Company having $0 in stock-based compensation expenses during the six months ended June 30, 2023 compared to $310,200 of stock-based compensation during the six months ended June 30, 2022 offset by an increase in rent expense of $12,850, an increase of $12,500 in litigation settlement expenses ($462,500 and $450,000 for the six months ended June 30, 2023 and 2022, respectively) and an increase of $123,823 in research and development expenses from $323,789 in the six months ended June 30, 2023 compared to $199,966 in the six months ended June 30, 2022.

Table of Contents

The decrease in stock-based compensation was due to the Company having $0 stock-based compensation expense during the six months ended June 30, 2023 compared to the Company having issued 645,000 shares of common stock for services valued at $310,200 during the six months ended June 30, 2022.

Other income (expense) for the six months ended June 30, 2023 and 2022 was $(136,186) and $(134,003), respectively. The increase in other expense was due to an increase in total interest expense of $35,026 offset by a decrease in loss on debt settlement of $32,843 during the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The increase in interest expense was primarily due to the Company having a larger outstanding balance of interest bearing promissory notes along with $17,648 of debt discount amortization expense during the six months ended June 30, 2023 compared to $0 during the six months June 30, 2022.

The decrease in the loss on settlement of debt was due to the Company issuing common stock with a fair value of $424,782 for the settlement of an aggregate of $344,250 of accrued liabilities and accrued liabilities – related party during the six months ended June 30, 2023 compared to the Company issuing common stock with a fair value of $304,001 for the settlement of an aggregate of $190,626 of accrued liabilities and accrued liabilities – related parties during the six months ended June 30, 2022.

Our net loss for the six months ended June 30, 2023 was $1,665,617 as compared to net loss of $1,843,301 for the comparable period of the prior year. The decrease in the net loss was due to the Company having a decrease in operating expenses of $179,867 offset by an increase in other expenses from $134,003 during the six months ended June 30, 2022 to $136,186 for the six months ended June 30, 2023 as explained above.

Financial Condition, Liquidity and Capital Resources

As of June 30, 2023, the Company had a negative working capital of $1,994,204. The Company has not yet attained a level of operations which will allow it to meet its current overhead expense obligations. The report of our independent registered public accounting firm on our 2022 financial statements includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The Company has been focusing its capital and resources towards seeking a Class III PMA for its HemoStyp technology, and has funded its initial operations with private placements, and unsecured loans from related parties. There can be no assurance that adequate financing will continue to be available to the Company and, if available, on terms that are favorable to the Company. Our ability to continue as a going concern is also dependent on many events outside of our direct control, including, among other things, our ability to achieve our business goals and objectives, as well as improvement in the economic climate.

During 2022, the Company entered into a common stock purchase agreement (“CSPA”) with White Lion, which gives the Company the right, but not the obligation, to require White Lion to purchase up to $10,000,000 of the Company’s common stock, subject to certain limitations and conditions set forth in the CSPA. As of the date of this filing, the Company has received approximately $1,535,794 in proceeds from White Lion to pay for its operations and finalization of its Class III PMA application. The sale of additional equity or convertible debt securities would be dilutive to our shareholders. In addition, economic conditions and actions by policymaking bodies are contributing to rising interest rates and significant capital market volatility, which, along with increases in our borrowing levels, could increase our future borrowing costs.

Cash Flows

The Company’s cash on hand at June 30, 2023 and December 31, 2022 was $133,601 and $13,377, respectively.

Table of Contents

The following table summarizes selected items from our statements of cash flows for the six months ended June 30, 2023 and 2022:

	For the Six Months Ended June 30,
	2023			2022
Net cash used in operating activities	$	(1,019,370	)	$	(399,189	)
Net cash used in investing activities		(2,850	)		(40,500	)
Net cash provided by financing activities		1,142,444			424,306

Net increase (decrease) in cash and cash equivalents	$	120,224		$	(15,383	)

Net Cash Used in Operating Activities

Net cash used in operating activities for the six months ended June 30, 2023 was $1,019,370. The Company had net loss of $1,665,617 offset by amortization expense of $2,025, amortization of debt discount of $17,648, stock issued for litigation settlement of $462,500 and a loss on debt settlement of $80,532, a decrease in inventory of $1,132, a decrease in prepaid and other current assets of $15,369 and an increase in accrued liabilities - related party of $229,711. The Company also had a decrease in accounts payable and accrued expenses of $12,670 and a decrease in accrued litigation settlement of $150,000.

Net cash used in operating activities for the six months ended June 30, 2022 was $399,189. The Company had net loss of $1,843,301 offset by stock for services and compensation of $310,200, amortization expense of $2,025, a loss on debt settlement of $113,375, an increase in accounts payable and accrued expenses of $500,774, an increase in accrued liabilities - related party of $146,944 and an increase in accrued litigation settlement of $380,000 and an increase in prepaid and other current assets of $9,206.

Table of Contents

Net Cash Used in Investing Activities

The Company paid $2,850 related to a security deposit during the six months ended June 30, 2023.

The Company paid $40,500 related to the patent application fees during the six months ended June 30, 2022.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2023 was $1,142,444. This was due to the result of the Company receiving $1,151,580 in proceeds from the sale of stock offset by making payments of $9,136 on a loan payable.

Net cash provided by financing activities for the six months ended June 30, 2022 was $424,306. This was due to the result of the Company receiving $77,292 in proceeds from the sale of stock and receiving $383,275 from related party loans offset by making payments of $36,261 on loan payable.

Off-Balance Sheet Arrangements

As of June 30, 2023, we have no off-balance sheet arrangements.

Critical Accounting Estimates

The preparation of financial statements in conformity with generally accepted accounting principles of the United States (“GAAP”) requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses in the financial statements and accompanying notes. Critical accounting estimates are those estimates made in accordance with GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on the financial condition or results of operations of the Company. Based on this definition, we have the critical accounting estimates identified below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results which are found in Note 2 – Significant Accounting Policies of our 2022 Annual Report on Form 10-K and Note 2 – Significant Accounting Policies in the accompanying financial statements. Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.

Stock-Based Compensation

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company is in the process of implementing disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the ‘‘Exchange Act’’), that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer and Principal Financial Officer to allow timely decisions regarding required disclosure.

As of June 30, 2023, the Chief Executive Officer and the Principal Financial Officer carried out an assessment of the effectiveness of the design and operation of our disclosure controls and procedures and concluded that the Company’s disclosure controls and procedures were not effective.

Changes in Internal Control over Financial Reporting

During the six months ended June 30, 2023, there were no changes in our system of internal controls over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

Management does not believe there have been any material changes to the risk factors listed in Part I, “Item 1A, Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2022. These risk factors should be carefully considered with the information provided elsewhere in this report, which could materially adversely affect our business, financial condition or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following summarizes all sales of our unregistered securities from January 1, 2023 through June 30, 2023. The securities in the below-referenced transactions were (i) issued without registration and (ii) were subject to restrictions under the Securities Act and the securities laws of certain states, in reliance on the private offering exemptions contained in Sections 4(a)(2), 4(a)(6) and/or 3(b) of the Securities Act and on Regulation D promulgated under the Securities Act, and in reliance on similar exemptions under applicable state laws as transactions not involving a public offering. No placement or underwriting fees were paid in connection with these transactions. All cash proceeds from the sale of securities were used for working capital purposes.

Date of Sale	Title of Security	Number Sold	Consideration Received	Purchaser/Recipient
January 2023	Common Stock	937,500	$187,500 of accrued liabilities	Officers and consultants
January 2023	Common Stock	1,135,000	$249,399 in cash	White Lion (1)
February 2023	Common Stock	1,000,000	$202,733 in cash	White Lion (1)
March 2023	Common Stock	400,000	$73,173 in cash	White Lion (1)
March 2023	Common Stock	400,000	$71,717 in cash	White Lion (1)
March 2023	Common Stock	1,850,000	$462,500 to settle litigation	Philip Forman
April 2023	Common Stock	979,688	$156,750 of accrued liabilities	Officers and consultants
April 2023	Common Stock	450,000	$86,524 in cash	White Lion (1)
May 2023	Common Stock	800,000	$139,797 in cash	White Lion (1)
June 2023	Common Stock	1,200,000	$277,686 in cash	White Lion (1)
June 2023	Common Stock	1,100,000	$311,820 stock subscription receivable	White Lion (1)

(1)

Issued by the Company to White Lion Capital, LLC pursuant to the terms of the Common Stock Purchase Agreement dated September 1, 2022, as amended.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Table of Contents

Item 6. Exhibits

The following exhibits are filed with this report, or incorporated by reference as noted:

3.1		Articles of Incorporation of the Company dated February 28, 1997 (1)

3.2		Amendment to Articles of Incorporation (1)

3.3		By-laws of the Company (2)

3.4		August 2015 Amendment to Articles of Incorporation (3)

10.1		Services Agreement with Louis Schiliro (4)

10.2		Restricted Stock Unit Agreement – Louis Schiliro (5)

10.3		Restricted Stock Unit Agreement – Doug Beplate (5)

10.4		Services Agreement with Brian Thom (6)

10.5		Restricted Stock Unit Agreement - Brian Thom (6)

10.6		Services Agreement with Kristofer Heaton (7)

10.7		Restricted Stock Unit Agreement - Kristofer Heaton (7)

10.8		Amendment to Restricted Stock Unit Agreement – Brian Thom (8)

10.9		Restricted Stock Unit Agreement – Robert Denser (8)

10.10		Stock Purchase Agreement dated September 1, 2022 between the Company and White Lion Capital LLC (9)

10.11		Amendment to Stock Purchase Agreement dated January 25, 2023 (10)

31.1		Certification of Principal Executive Officer*

31.2		Certification of Principal Financial Officer*

32.1		Section 1350 Certificate by Principal Executive Officer*

32.2		Section 1350 Certificate by Principal Financial Officer*

99.1		2019 Employee Benefit and Consulting Services Compensation Plan (11)

Table of Contents

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

___________

* Filed herewith.

(1)	Incorporated by reference to the Company’s Form 10-Q for the quarter ended September 30, 2014.

(2)	Incorporated by reference to the Company’s Form 10-Q for the quarter ended June 30, 2022.

(3)	Incorporated by reference to Form 8-K dated August 7, 2015 – date of earliest event filed on August 10, 2015.

(4)	Incorporated by reference to the Company’s Form 10-Q for the quarter ended June 30, 2018.

(5)	Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2018.

(6)	Incorporated by reference to the Form 8-K dated December 2, 2020

(7)	Incorporated by reference to the Form 8-K dated January 11, 2021

(8)	Incorporated by reference to the Form 8-K dated June 23, 2022

(9)	Incorporated by reference to the Form 8-K dated September 1, 2022

(10)	Incorporated by reference to the Company’s Form 10-K for the year ended December 31, 2022

(11)	Incorporated by reference to Form S-8 dated November 1, 2019

Table of Contents

SIGNATURES

Pursuant to the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UNITED HEALTH PRODUCTS, INC.

Dated: August 9, 2023	By:	/s/ Brian Thom
		Brian Thom
		Principal Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Signatures		Title	Date

By:	/s/ Brian Thom		August 9, 2023
	Brian Thom	Chief Executive Officer, Principal Executive Officer and Director

By:	/s/ Kristofer Heaton	Principal Financial Officer	August 9, 2023
	Kristofer Heaton

By:	/s/ Robert Denser	Director	August 9, 2023
	Robert Denser

EX-31.1 2 ueec_ex311.htm CERTIFICATION ueec_ex311.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Brian Thom certifies that:

1.

I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

2

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023

By:

/s/ Brian Thom

Brian Thom

Principal Executive Officer

EX-31.2 3 ueec_ex312.htm CERTIFICATION ueec_ex312.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Kristofer Heaton certifies that:

1.

I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

2

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023

By

/s/ Kristofer Heaton

Kristofer Heaton

Principal Financial Officer

EX-32.1 4 ueec_ex321.htm CERTIFICATION ueec_ex321.htm

EXHIBIT 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Brian Thom, Principal Executive Officer of United Health Products, Inc. (the “Company”) of the Company, hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned have set their hands hereto as of the August 9, 2023.

By:

/s/ Brian Thom

Brian Thom

Principal Executive Officer

EX-32.2 5 ueec_ex322.htm CERTIFICATION ueec_ex322.htm

EXHIBIT 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), Kristofer Heaton, Principal Financial Officer of United Health Products, Inc. (the “Company”) of the Company, hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, to which this Certification is attached as Exhibit 32.2 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned have set their hands hereto as of the August 9, 2023.

By:

/s/ Kristofer Heaton

Kristofer Heaton

Principal Financial Officer

EX-101.SCH 6 ueec-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Condensed Statement of Stockholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Organization and Basis of Preparation link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Promissory Note Payable link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Issuances of Securities link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Accrued Litigation Settlement link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Issuances of Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Promissory Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Convertible Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Issuances of Securities (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Issuances of Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Accrued Litigation Settlement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Litigation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Leases (Details 2) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 ueec-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current Condensed Balance Sheets Statement [Table] Statement [Line Items] Class of Stock [Axis] Series A Convertible Preferred Stock Member ASSETS Current Assets Cash and Cash Equivalents Inventory Prepaid and other current assets Total current assets [Assets, Current] Deferred offering costs Operating lease right-of-use asset Security deposit Patents, net TOTAL ASSETS [Assets] Current Liabilities Accounts payable and accrued expenses Accrued liabilities - related parties Accrued litigation settlement Operating lease liability - current Promissory note payable Loans payable - related parties Convertible notes payable, net of debt discount Convertible notes payable - related party, net of debt discount Total current liabilities [Liabilities, Current] Operating lease liability - long-term TOTAL LIABILITIES [Liabilities] Commitments and Contingencies Stockholders' Deficit Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding Common Stock - $0.001 par value, 300,000,000 shares Authorized, 241,123,222 and 230,871,034 shares issued and outstanding at June 30, 2023 and December 31, 2022 Subscription Receivable [Common Stock, Share Subscribed but Unissued, Subscriptions Receivable] Additional Paid-In Capital [Additional Paid in Capital] Accumulated Deficit [Retained Earnings (Accumulated Deficit)] Total Stockholders' Deficit [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT [Liabilities and Equity] Common stock, shares par value Preferred stock, shares par value Common stock, shares authorized Preferred stock, shares authorized Common stock, shares issued Preferred stock, shares issued Common stock, shares outstanding Preferred stock, shares outstanding Condensed Statements of Operations (Unaudited) Revenues Operating Costs and Expenses Selling, general and administrative expenses Research and development Total Operating Expenses [Operating Expenses] Loss from Operations [Operating Income (Loss)] Other Income (Expenses) Interest expense [Interest Expense] Interest expense - related party [Interest expense - related party] Loss on settlement of debt Total other income (expenses) [Other Nonoperating Income (Expense)] Net Loss [Net Income (Loss) Attributable to Parent] Net Loss per common share: Basic and diluted Weighted average number of shares outstanding Condensed Statement of Stockholders Equity (Unaudited) Equity Components [Axis] Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Subscription Receivable [Subscription Receivable] Accumulated Deficit Retained Earnings [Member] Balance, shares [Shares, Issued] Balance, amount Issuance of common stock for services, shares Issuance of common stock for services, amount Sale of common stock, shares Sale of common stock, amount Common stock issued to settle accounts payable and accrued liabilities, shares Common stock issued to settle accounts payable and accrued liabilities, amount Net Loss Issuance of common stock for services - related party, shares Issuance of common stock for services - related party, amount Common stock issued to settle accounts payable and accrued liabilities - related party, shares Common stock issued to settle accounts payable and accrued liabilities - related party, amount Cancellation of common stock, shares Cancellation of common stock, amount Common stock issued to settle accrued liabilities - related party, shares Common stock issued to settle accrued liabilities - related party, amount Common stock issued to settle accrued liabilities, shares Common stock issued to settle accrued liabilities, amount Common stock issued for a stock subscription receivable, shares Common stock issued for a stock subscription receivable, amount Amortization of deferred offering costs Common stock issued for litigation settlement, shares Common stock issued for litigation settlement, amount Balance, shares Balance, amount Condensed Statements of Cash Flows (Unaudited) Cash Flows from Operating Activities: Net (Loss) [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities: Stock for services and compensation Amortization expense Amortization of debt discount Loss on settlement of debt Stock issued for litigation settlement Changes in assets and liabilities: Inventory [Increase (Decrease) in Inventories] Prepaid and other current assets [Increase (Decrease) in Prepaid Expense and Other Assets] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Accrued liabilities - related party Accrued litigation settlement [Accrued litigation settlement] Net Cash Used In Operating Activities [Net Cash Provided by (Used in) Operating Activities] Cash Flows from Investing Activities: Purchase of intangible assets [Payments to Acquire Intangible Assets] Security deposit [Security deposit] Net Cash Used in Investing Activities [Net Cash Provided by (Used in) Investing Activities] Cash Flows from Financing Activities: Proceeds from related party Repayments on loan payable [Repayments of Debt] Proceeds from sale of common stock Cash flow provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Increase (decrease) in Cash and Cash Equivalents [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash and Cash Equivalents - Beginning of period CASH AND CASH EQUIVALENTS - END OF PERIOD Supplemental cash flow information: Cash paid for interest Cash paid for income taxes Non-cash Investing & Financing Activities: Cancellation of common stock Common stock issued for subscription receivable Amortization of deferred offering costs [Amortization of deferred offering costs] Initial recognition of operating lease right-of-use asset and operating lease liability Common stock issued to settle accrued liabilities - related party Accounts payable and accrued expenses paid with promissory note payable Common stock issued to settle accrued liabilities Accrued litigation settlement paid with loan payable Organization and Basis of Preparation Organization and Basis of Preparation Business Description and Basis of Presentation [Text Block] Significant Accounting Policies Significant Accounting Policies Significant Accounting Policies [Text Block] Related Party Transactions Related Party Transactions Related Party Transactions Disclosure [Text Block] Promissory Note Payable Promissory Note Payable Debt Disclosure [Text Block] Convertible Notes Convertible Notes [Convertible Notes] Issuances of Securities Issuances of Securities Stockholders' Equity Note Disclosure [Text Block] Accrued Litigation Settlement Accrued Litigation Settlement [Accrued Litigation Settlement] EX-101.CAL 8 ueec-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 ueec-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 ueec-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 09, 2023
Cover [Abstract]
Entity Registrant Name	UNITED HEALTH PRODUCTS, INC.
Entity Central Index Key	0001096938
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		241,123,222
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-27781
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	84-1517723
Entity Address Address Line 1	526 Commerce Circle
Entity Address Address Line 2	Suite #120
Entity Address City Or Town	Mesquite
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89027
City Area Code	475
Local Phone Number	755-1005
Entity Interactive Data Current	Yes

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash and Cash Equivalents	$ 133,601	$ 13,377
Inventory	33,598	34,730
Prepaid and other current assets	7,563	22,932
Total current assets	174,762	71,039
Deferred offering costs	132,281	243,039
Operating lease right-of-use asset	89,575	0
Security deposit	2,850	0
Patents, net	34,425	36,450
TOTAL ASSETS	433,893	350,528
Current Liabilities
Accounts payable and accrued expenses	1,116,562	1,255,232
Accrued liabilities - related parties	174,040	172,579
Accrued litigation settlement	150,000	300,000
Operating lease liability - current	22,208	0
Promissory note payable	10,000	9,136
Loans payable - related parties	4,000	4,000
Convertible notes payable, net of debt discount	201,935	196,177
Convertible notes payable - related party, net of debt discount	490,221	478,331
Total current liabilities	2,168,966	2,415,455
Operating lease liability - long-term	67,367	0
TOTAL LIABILITIES	2,236,333	2,415,455
Commitments and Contingencies	0	0
Stockholders' Deficit
Common Stock - $0.001 par value, 300,000,000 shares Authorized, 241,123,222 and 230,871,034 shares issued and outstanding at June 30, 2023 and December 31, 2022	241,123	230,871
Subscription Receivable	(311,820)	(50,550)
Additional Paid-In Capital	74,009,817	71,830,695
Accumulated Deficit	(75,741,560)	(74,075,943)
Total Stockholders' Deficit	(1,802,440)	(2,064,927)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	433,893	350,528
Series A Convertible Preferred Stock Member
Stockholders' Deficit
Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding	$ 0	$ 0

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	241,123,222	230,871,034
Common stock, shares outstanding	241,123,222	230,871,034
Series A Convertible Preferred Stock Member
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Statements of Operations (Unaudited)
Revenues	$ 0	$ 0	$ 0	$ 0
Operating Costs and Expenses
Selling, general and administrative expenses	370,343	607,186	1,205,642	1,509,332
Research and development	105,113	147,611	323,789	199,966
Total Operating Expenses	475,456	754,797	1,529,431	1,709,298
Loss from Operations	(475,456)	(754,797)	(1,529,431)	(1,709,298)
Other Income (Expenses)
Interest expense	(8,329)	(205)	(16,656)	(285)
Interest expense - related party	(19,532)	(11,535)	(38,998)	(20,343)
Loss on settlement of debt	(19,594)	(112,500)	(80,532)	(113,375)
Total other income (expenses)	(47,455)	(124,240)	(136,186)	(134,003)
Net Loss	$ (522,911)	$ (879,037)	$ (1,665,617)	$ (1,843,301)
Net Loss per common share:
Basic and diluted	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding	238,269,719	229,737,399	235,376,226	229,257,932

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Stockholders Equity (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Subscription Receivable	Accumulated Deficit
Balance, shares at Dec. 31, 2021		228,667,229
Balance, amount at Dec. 31, 2021	$ (1,141,894)	$ 228,667	$ 71,017,881	$ 0	$ (72,388,442)
Issuance of common stock for services, shares		20,000
Issuance of common stock for services, amount	10,200	$ 20	10,180	0	0
Sale of common stock, shares		184,028
Sale of common stock, amount	77,292	$ 184	77,108	0	0
Common stock issued to settle accounts payable and accrued liabilities, shares		6,252
Common stock issued to settle accounts payable and accrued liabilities, amount	4,001	$ 6	3,995	0	0
Net Loss	(964,264)	$ 0		0	(964,264)
Balance, shares at Mar. 31, 2022		228,877,509
Balance, amount at Mar. 31, 2022	(2,014,665)	$ 228,877	71,109,164	0	(73,352,706)
Balance, shares at Dec. 31, 2021		228,667,229
Balance, amount at Dec. 31, 2021	(1,141,894)	$ 228,667	71,017,881	0	(72,388,442)
Net Loss	(1,843,301)
Balance, shares at Jun. 30, 2022		229,877,509
Balance, amount at Jun. 30, 2022	(2,293,702)	$ 229,877	71,708,164	0	(74,231,743)
Balance, shares at Mar. 31, 2022		228,877,509
Balance, amount at Mar. 31, 2022	(2,014,665)	$ 228,877	71,109,164	0	(73,352,706)
Issuance of common stock for services, shares		200,000
Issuance of common stock for services, amount	96,000	$ 200	95,800	0	0
Common stock issued to settle accounts payable and accrued liabilities, shares		20,000
Common stock issued to settle accounts payable and accrued liabilities, amount	96,000	$ 200	95,800	0	0
Net Loss	(879,037)	$ 0	0	0	(879,037)
Issuance of common stock for services - related party, shares		425,000
Issuance of common stock for services - related party, amount	204,000	$ 425	203,575	0	0
Common stock issued to settle accounts payable and accrued liabilities - related party, shares		425,000
Common stock issued to settle accounts payable and accrued liabilities - related party, amount	204,000	$ 425	203,575	0	0
Cancellation of common stock, shares		(250,000)
Cancellation of common stock, amount	0	$ (250)	250	0	0
Balance, shares at Jun. 30, 2022		229,877,509
Balance, amount at Jun. 30, 2022	(2,293,702)	$ 229,877	71,708,164	0	(74,231,743)
Balance, shares at Dec. 31, 2022		230,871,034
Balance, amount at Dec. 31, 2022	(2,064,927)	$ 230,871	71,830,695	(50,550)	(74,075,943)
Sale of common stock, shares		2,535,000
Sale of common stock, amount	575,855	$ 2,535	522,770	50,550	0
Net Loss	(1,142,706)	$ 0	0	0	(1,142,706)
Common stock issued to settle accrued liabilities - related party, shares		637,500
Common stock issued to settle accrued liabilities - related party, amount	168,938	$ 638	168,300	0	0
Common stock issued to settle accrued liabilities, shares		300,000
Common stock issued to settle accrued liabilities, amount	79,500	$ 300	79,200	0	0
Common stock issued for a stock subscription receivable, shares		400,000
Common stock issued for a stock subscription receivable, amount	0	$ 400	71,317	(71,717)	0
Amortization of deferred offering costs	(55,371)	$ 0	(55,371)	0	0
Common stock issued for litigation settlement, shares		1,850,000
Common stock issued for litigation settlement, amount	462,500	$ 1,850	460,650	0	0
Balance, shares at Mar. 31, 2023		236,593,534
Balance, amount at Mar. 31, 2023	(1,976,211)	$ 236,594	73,077,561	(71,717)	(75,218,649)
Balance, shares at Dec. 31, 2022		230,871,034
Balance, amount at Dec. 31, 2022	(2,064,927)	$ 230,871	71,830,695	(50,550)	(74,075,943)
Net Loss	$ (1,665,617)
Common stock issued for litigation settlement, shares	1,850,000
Balance, shares at Jun. 30, 2023		241,123,222
Balance, amount at Jun. 30, 2023	$ (1,802,440)	$ 241,123	74,009,817	(311,820)	(75,741,560)
Balance, shares at Mar. 31, 2023		236,593,534
Balance, amount at Mar. 31, 2023	(1,976,211)	$ 236,594	73,077,561	(71,717)	(75,218,649)
Sale of common stock, shares		2,450,000
Sale of common stock, amount	575,725	$ 2,450	501,558	71,717	0
Net Loss	(522,911)	$ 0	0	0	(522,911)
Common stock issued to settle accrued liabilities - related party, shares		567,188
Common stock issued to settle accrued liabilities - related party, amount	102,093	$ 566	101,527	0	0
Common stock issued to settle accrued liabilities, shares		412,500
Common stock issued to settle accrued liabilities, amount	74,251	$ 413	73,838	0	0
Common stock issued for a stock subscription receivable, shares		1,100,000
Common stock issued for a stock subscription receivable, amount	0	$ 1,100	310,720	(311,820)	0
Amortization of deferred offering costs	(55,387)	$ 0	(55,387)	0	0
Balance, shares at Jun. 30, 2023		241,123,222
Balance, amount at Jun. 30, 2023	$ (1,802,440)	$ 241,123	$ 74,009,817	$ (311,820)	$ (75,741,560)

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows from Operating Activities:
Net (Loss)	$ (1,665,617)	$ (1,843,301)
Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:
Stock for services and compensation	0	310,200
Amortization expense	2,025	2,025
Amortization of debt discount	17,648	0
Loss on settlement of debt	80,532	113,375
Stock issued for litigation settlement	462,500	0
Changes in assets and liabilities:
Inventory	1,132	0
Prepaid and other current assets	15,369	(9,206)
Accounts payable and accrued expenses	(12,670)	500,774
Accrued liabilities - related party	229,711	146,944
Accrued litigation settlement	(150,000)	380,000
Net Cash Used In Operating Activities	(1,019,370)	(399,189)
Cash Flows from Investing Activities:
Purchase of intangible assets	0	(40,500)
Security deposit	(2,850)	0
Net Cash Used in Investing Activities	(2,850)	(40,500)
Cash Flows from Financing Activities:
Proceeds from related party	0	383,275
Repayments on loan payable	(9,136)	(36,261)
Proceeds from sale of common stock	1,151,580	77,292
Cash flow provided by financing activities	1,142,444	424,306
Increase (decrease) in Cash and Cash Equivalents	120,224	(15,383)
Cash and Cash Equivalents - Beginning of period	13,377	21,799
CASH AND CASH EQUIVALENTS - END OF PERIOD	133,601	6,416
Supplemental cash flow information:
Cash paid for interest	15	285
Cash paid for income taxes	0	0
Non-cash Investing & Financing Activities:
Cancellation of common stock	0	250
Common stock issued for subscription receivable	311,820	0
Amortization of deferred offering costs	110,758	0
Initial recognition of operating lease right-of-use asset and operating lease liability	92,425	0
Common stock issued to settle accrued liabilities - related party	218,250	127,500
Accounts payable and accrued expenses paid with promissory note payable	10,000	0
Common stock issued to settle accrued liabilities	126,000	63,126
Accrued litigation settlement paid with loan payable	$ 0	$ 100,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Basis of Preparation

6 Months Ended

Jun. 30, 2023

Organization and Basis of Preparation

Organization and Basis of Preparation

Note 1. Organization and Basis of Preparation

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Significant Accounting Policies

Significant Accounting Policies

Note 2. Significant Accounting Policies

Going Concern

Cash and Cash Equivalents

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Use of Estimates

Fair Value Measurements

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Revenue Recognition

Trade Accounts Receivable and Concentration Risk

Inventory

Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of work-in process.

June 30,

2023

December 31,

2022

Finished goods

33,598

34,730

Total inventory

33,598

34,730

Stock Based Compensation

Per Share Information

Patents

Accumulated amortization as of June 30, 2023 and December 31, 2022 was $6,075 and $4,050, respectively. Amortization expense for the six months ended June 30, 2023 and 2022 was $2,025, respectively.

Future Amortization Expense

Year	Amount
2023 (remaining)	$	2,025
2024		4,050
2025		4,050
2026		4,050
2027		4,050
Thereafter		16,200
	$	34,425

Impairment of Long-lived Assets

Deferred Offering Costs

Advertising and Marketing Costs

Research and Development

Leases

New Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2023

Related Party Transactions

Related Party Transactions

Note 3. Related Party Transactions

Convertible notes payable - related parties

Loans payable – related parties

Accrued liabilities – related parties

As of June 30, 2023 and December 31, 2022, $108,776 and $127,500 of accrued compensation and reimbursable expenses was due to the Company’s officers and management, respectively.

Equity transactions

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Promissory Note Payable

6 Months Ended

Jun. 30, 2023

Promissory Note Payable

Promissory Note Payable

Note 4. Promissory Note Payable

During the six months ended June 30, 2023, the Company paid the remaining principal balance of $9,136. As of June 30, 2023, the principal balance and accrued interest was $0.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes

6 Months Ended

Jun. 30, 2023

Convertible Notes

Convertible Notes

Note 5. Convertible Notes

XML 22 R12.htm IDEA: XBRL DOCUMENT

Issuances of Securities

6 Months Ended

Jun. 30, 2023

Issuances of Securities

Issuances of Securities

Note 6. Issuances of Securities

Share issuances 2022

During the six months ended June 30, 2022, the Company had the following common stock transactions:

	·	184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292.
	·	206,252 shares of commons stock with a fair value of $100,001 were issued to various consultants to settle $63,126 of accrued liabilities resulting in a loss on settlement of debt of $36,875.
	·	200,000 shares of common stock with a fair value of $96,000 were issued to consultants for services.
	·	425,000 shares of common stock were issued to settle $127,500 of accrued liabilities – related party resulting in a loss of settlement of debt of $76,500.
	·	425,000 shares of common stock with a fair value of $204,000 were issued to officers and a former officer of the Company for services.
	·	250,000 shares of common stock were cancelled reducing common stock by $250 and increasing additional paid-in capital by the same.
	·	20,000 shares of common stock with a fair value of $10,200 were issued for legal services.

Share issuances 2023

During the six months ended June 30, 2023, the Company had the following common stock transactions:

	·	1,204,688 shares of common stock with a fair value of $271,031 were issued to officers and management of the Company to settle $218,250 of accrued liabilities (see Note 3) resulting in a loss on settlement of debt of $52,781.
	·	712,500 shares of common stock with a fair value of $153,751 were issued to consultants to settle $126,000 of accrued liabilities resulting in a loss on debt settlement of $27,751.
	·	5,385,000 shares of common stock were sold for $1,151,580, net of legal and administrative fees of $6,600 and which included a payment of $50,550 for a subscription receivable, under the Company’s common stock purchase agreement with White Lion. White Lion also purchased 1,100,000 shares for proceeds of $311,820 which were received in July 2023 and is shown as a subscription receivable in the balance sheet as of June 30, 2023.
	·	1,850,000 shares of common stock with a fair value of $462,500 were issued to settle litigation (see Note 8).

Restricted stock units

Activity related to our restricted stock units during the three months ended June 30, 2023 was as follows:

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2022		47,665,000	$	0.54
Units granted		-	$	-
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at June 30, 2023		47,665,000	$	0.54

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Accrued Litigation Settlement

6 Months Ended

Jun. 30, 2023

Accrued Litigation Settlement

Accrued Litigation Settlement

Note 7. Accrued Litigation Settlement

	·	$50,000 upon the entry of the judgment;
	·	$100,000 within 90 days of the entry of the judgment;
	·	$150,000 within 180 days of the entry of the judgment; and
	·	$150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961

XML 24 R14.htm IDEA: XBRL DOCUMENT

Litigation

6 Months Ended

Jun. 30, 2023

Litigation

Litigation

Note 8. Litigation

XML 25 R15.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2023

Leases

Leases

Note 9. Leases

The components of lease expense and supplemental cash flow information related to the lease for the period are as follows:

	Six Months Ended June 30, 2023
Lease Cost
Operating lease cost (included in general and administrative in the Company’s statement of operations)	$	2,850

Other Information
Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2023	$	2,850
Weighted average remaining lease term – operating leases (in years)	2.92 years
Average discount rate – operating lease		10	%

The supplemental balance sheet information related to leases for the period is as follows:

	At June 30, 2023		At December 31, 2022
Operating leases
Remaining right-of-use assets	$	89,575	$	-

Short-term operating lease liabilities	$	22,208	$	-
Long-term operating lease liabilities	$	67,367	$	-
Total operating lease liabilities	$	89,575	$	-

Maturities of the Company’s undiscounted lease liabilities are as follows:

Year Ending	Operating Leases
2023 (Remaining)	$	17,100
2024		34,998
2025		36,394
2026		15,410
Total lease payments		103,902
Less: Imputed interest/present value discount		(14,327	)
Present value of lease liabilities	$	89,575

XML 26 R16.htm IDEA: XBRL DOCUMENT

Subsequent Event

6 Months Ended

Jun. 30, 2023

Subsequent Event

Subsequent Event

Note 10. Subsequent Events

XML 27 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2023

Significant Accounting Policies

Going Concern

Cash and Cash Equivalents

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

Use of Estimates

Fair Value Measurements

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Revenue Recognition

Trade Accounts Receivable and Concentration Risk

Inventory

Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of work-in process.

June 30,

2023

December 31,

2022

Finished goods

33,598

34,730

Total inventory

33,598

34,730

Stock Based Compensation

Per Share Information

Patents

Accumulated amortization as of June 30, 2023 and December 31, 2022 was $6,075 and $4,050, respectively. Amortization expense for the six months ended June 30, 2023 and 2022 was $2,025, respectively.

Future Amortization Expense

Year	Amount
2023 (remaining)	$	2,025
2024		4,050
2025		4,050
2026		4,050
2027		4,050
Thereafter		16,200
	$	34,425

Impairment of Long-lived Assets

Deferred Offering Costs

Advertising and Marketing Costs

Research and Development

Leases

New Accounting Pronouncements

XML 28 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Significant Accounting Policies

Schedule of Inventory

June 30,

2023

December 31,

2022

Finished goods

33,598

34,730

Total inventory

33,598

34,730

Schedule of Future Amortization Expense

Year	Amount
2023 (remaining)	$	2,025
2024		4,050
2025		4,050
2026		4,050
2027		4,050
Thereafter		16,200
	$	34,425

XML 29 R19.htm IDEA: XBRL DOCUMENT

Issuances of Securities (Tables)

6 Months Ended

Jun. 30, 2023

Issuances of Securities

Schedule of Restricted Stock Units

			Weighted
			Average
			Grant
	Number of		Date Fair
	Units		Value
Total awards outstanding at December 31, 2022		47,665,000	$	0.54
Units granted		-	$	-
Units Exercised/Released		-	$	-
Units Cancelled/Forfeited		-	$	-
Total awards outstanding at June 30, 2023		47,665,000	$	0.54

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2023

Leases

Schedule of lease expense and supplemental cash flow information

	Six Months Ended June 30, 2023
Lease Cost
Operating lease cost (included in general and administrative in the Company’s statement of operations)	$	2,850

Other Information
Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2023	$	2,850
Weighted average remaining lease term – operating leases (in years)	2.92 years
Average discount rate – operating lease		10	%

Schedule of supplemental balance sheet information

	At June 30, 2023		At December 31, 2022
Operating leases
Remaining right-of-use assets	$	89,575	$	-

Short-term operating lease liabilities	$	22,208	$	-
Long-term operating lease liabilities	$	67,367	$	-
Total operating lease liabilities	$	89,575	$	-

Schedule of undiscounted lease liabilities

Year Ending	Operating Leases
2023 (Remaining)	$	17,100
2024		34,998
2025		36,394
2026		15,410
Total lease payments		103,902
Less: Imputed interest/present value discount		(14,327	)
Present value of lease liabilities	$	89,575

XML 31 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Significant Accounting Policies
Finished goods	$ 33,598	$ 34,730
Total Inventory	$ 33,598	$ 34,730

XML 32 R22.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details 1) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Significant Accounting Policies
2023 (remaining)	$ 2,025
2024	4,050
2025	4,050
2026	4,050
2027	4,050
Thereafter	16,200
Future Amortization Expense	$ 34,425	$ 36,450

XML 33 R23.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Accumulated amortization	$ 6,075		$ 6,075		$ 4,050
Advertising and marketing expenses			57,536	$ 55,000
Research and development costs	$ 105,113	$ 147,611	323,789	199,966
Bad debt expense			0	0
Amortization expense			$ 2,025	2,025
Description of patent			straight-line basis over the estimated useful life of 10 years
Inventory used			$ 1,132	0
Impaired and written-off			$ 0	$ 0
Convertible Notes Payable [Member]
Potential antidilutive shares			1,406,300
Convertible Notes Payable - Related Parties [Member]
Potential antidilutive shares			3,552,376
Restricted Stock Units [Member]
Potential antidilutive shares			47,665,000	30,915,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Interest Rate					10.00%
Interest expense on convertible notes - related party	$ 19,426				$ 38,786
Share price							$ 0.35
Debt discount amortization related to OID	5,978		$ 0			$ 0
Accrued interest	55,592				55,592		$ 33,897
Loans payable - related parties	4,000				4,000		$ 4,000
Convertible Note Interest Rate							10.00%
Original Issue Discount Rate							7.00%
Original Issue Discount Rate							7.00%
Maturity Of Convertible Notes Payable							December 31, 2023
Conversion Of Common Stock							$ 0.35
Debt Discount					28,000
Unamortized Debt Discount	7,578				7,578		$ 16,998
Principal amount converted to convertible note payable							372,000
Accrued compensation	108,776				108,776		127,500
Stock issued during period, value	575,725	$ 575,855		$ 77,292
Operating Expenses	475,456		$ 754,797		1,529,431	1,709,298	4,000
Loans Payable Related Parties [Member]
Interest expense on related party	106				212	$ 0
Accrued interest	436				436		$ 224
Officers And Directors [Member]
Interest Rate							10.00%
Share price							$ 0.35
Accrued interest	9,236				9,236		$ 4,034
Original Issue Discount Rate							7.00%
Conversion Of Common Stock							$ 0.35
Debt Discount							$ 7,000
Unamortized Debt Discount	2,201				2,201		$ 4,671
Maturity Date							December 31, 2023
Loan To Company							$ 93,000
Equity transactions [Member]
Accrued compensation	218,250				$ 218,250
Stock issued during period, share					1,204,688
Stock issued during period, value					$ 271,031
Related parties [Member]
Accrued interest	$ 64,828				$ 64,828		$ 37,931

XML 35 R25.htm IDEA: XBRL DOCUMENT

Promissory Note Payable (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
Promissory Note Payable (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Promissory Note Payable
Accrues interest	$ 0			$ 0		$ 0
Interest rate	5.00%			5.00%		1.00%
Monthly payments				$ 9,136	$ 36,261	$ 9,136
Promissory note						100,000
Remaining principle balance on promissory note payable	$ 9,136			9,136		9,136
Accrued interest note	250			250		$ 0
Note payable amount payment				10,000
Accounts payable and accrued expenses on promissory note payable			$ 0	10,000
Interest expense	$ 125	$ 0		$ 250	$ 0
Maturity of convertible notes payable				December 31, 2023

XML 36 R26.htm IDEA: XBRL DOCUMENT

Convertible Notes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Convertible Notes (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Accrued Interest	$ 16,102		$ 16,102		$ 5,454
Maturity Date					December 31, 2023
Interest Rate					10.00%
Issuance Of Convertible Note					$ 93,000
Convertible Note Per Share price					$ 0.35
Share price					$ 0.35
Original Issue Discount Rate					7.00%
Interest expense	125	$ 0	250	$ 0
Debt discount amortization related to OID	2,895	$ 0	5,758	$ 0
Debt Discount					$ 14,525
Proceed from convertible notes					192,975
Convertible Notes Payable, Noncurrent					99,975
Unamortized debt discount	5,565		5,565		$ 11,323
Convertible Notes Payable [Member]
Interest expense	$ 8,204
Interest expense convertible note			$ 16,406

XML 37 R27.htm IDEA: XBRL DOCUMENT

Issuances of Securities (Details)	6 Months Ended
Issuances of Securities (Details)	Jun. 30, 2023 $ / shares shares
Issuances of Securities
Number of units total awards outstanding, beginning \| shares	47,665,000
Number of units total awards outstanding, ending \| shares	47,665,000
Weighted Average Grant Date Fair Value
Weighted average grant date fair value, total awards outstanding, beginning	$ 0.54
Weighted average grant date fair value, units granted	0
Weighted average grant date fair value, units exercised/released	0
Weighted average grant date fair value, units cancelled/forfeited	0
Weighted average grant date fair value, total awards outstanding, ending	$ 0.54

XML 38 R28.htm IDEA: XBRL DOCUMENT

Issuances of Securities (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
Issuances of Securities (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Repurchase common shares				$ 1,100,000
Restricted stock units, granted				47,665,000		47,665,000
Unrecognized compensation cost	$ 25,313,630			$ 25,313,630
Stock issued for litigation settlement				$ 462,500	$ 0
Common stock issued for litigation settlement, shares				1,850,000
Loss on settlement of debt	$ (19,594)	$ (112,500)		$ (80,532)	(113,375)
Subscription receivable				50,550
Proceeds from issuance of cost				311,820
Proceeds from issuance of cost				1,151,580	77,292
Legal and administrative fees				$ 6,600
Common stock, shares issued for service renderred, amount		$ 96,000	$ 10,200
Legal Counsels [Member]
Fair value of common stock					$ 10,200
Common stock, shares issued for service renderred, shares					20,000
Consultant [Member]
Common stock, shares issued for service renderred, shares					200,000
Common stock, shares issued for service renderred, amount					$ 96,000
Litigation Settlement [Member]
Common stock shares issued during the period					425,000
Fair value of common stock					$ 204,000
Share Issuances [Member]
Common stock shares issued during the period				712,500	425,000
Accrued liabilities related party				$ 126,000	$ 127,500
Loss on settlement of debt				27,751	76,500
Fair value of common stock				$ 153,751
Share Issuances 2021 and 2022 [Member]
Common stock shares issued during the period				1,204,688
Accrued liabilities				$ 218,250
Loss on settlement of debt				52,781
Fair value of common stock				$ 271,031
Consultant Agreement [Member]
Accrued liabilities related party					63,126
Loss on settlement of debt					36,875
Fair value of common stock					$ 100,001
Common stock, shares issued for service renderred, shares					206,252
Non Affiliated Investor [Member] \| Private Placement [Member]
Common stock shares issued during the period					184,028
Proceeds from issuance of cost					$ 77,292
White Lion Capital [Member]
Common stock shares issued during the period				5,385,000
Fair value of common stock				$ 1,151,580
Common Stock [Member]
Common stock shares cancellations					250,000
Increasing additional paid-in capital					$ 250

XML 39 R29.htm IDEA: XBRL DOCUMENT

Accrued Litigation Settlement (Details Narrative) - USD ($)	1 Months Ended
	Jun. 15, 2022	Jun. 30, 2023	Dec. 31, 2022
Civil penalty amount	$ 450,000
Total civil penalty amount		$ 300,000
Accrued litigation settlement		$ 150,000	$ 300,000
Installment One [Member]
Civil penalty amount	50,000
Installment Two [Member]
Civil penalty amount	100,000
Installment Four [Member]
Civil penalty amount	150,000
Installment Three [Member]
Civil penalty amount	$ 150,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Litigation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Litigation (Details Narrative) - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023
Stock issued during period, value	$ 96,000	$ 10,200
Former Chief Executive Officer and Chief Medical Advisor [Member]
Stock issued during period, shares			1,850,000
Stock issued during period, value			$ 462,500

XML 41 R31.htm IDEA: XBRL DOCUMENT

Leases (Details)	6 Months Ended
Leases (Details)	Jun. 30, 2023 USD ($)
Leases
Operating lease cost (included in general and administrative in the Company's statement of operations)	$ 2,850
Average discount rate - operating lease	10.00%
Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2023	$ 2,850
Weighted average remaining lease term - operating leases (in years)	2 years 11 months 1 day

XML 42 R32.htm IDEA: XBRL DOCUMENT

Leases (Details 1) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Leases
Remaining right-of-use assets	$ 89,575	$ 0
Short-term operating lease liabilities	22,208	0
Long-term operating lease liabilities	67,367	0
Total operating lease liabilities	$ 89,575	$ 0

XML 43 R33.htm IDEA: XBRL DOCUMENT

Leases (Details 2)	Jun. 30, 2023 USD ($)
Leases
2023 (Remaining)	$ 17,100
2024	34,998
2025	36,394
2026	15,410
Total lease payments	103,902
Less Imputed Interest	(14,327)
Total	$ 89,575

XML 44 R34.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative)	6 Months Ended
Leases (Details Narrative)	Jun. 30, 2023 USD ($)
Leases
Description of leases security deposit and monthly lease payments	the Company entered into 36-month operating lease, which provides for approximately 1,800 square feet of office space, that commenced on June 1, 2023 and ends on May 31, 2026. The lease required a $2,850 security deposit and monthly lease payments are $2,850 the first year of the lease, $2,964 the second year and $3,082 the third year
ROU asset and lease liability	$ 92,425

XML 45 R35.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - Subsequent Event - USD ($)	2 Months Ended
	Oct. 01, 2023	Aug. 01, 2023
Payments due	$ 50,000
Payments made by the company		$ 50,000

XML 46 ueec_10q_htm.xml IDEA: XBRL DOCUMENT 0001096938 2023-01-01 2023-06-30 0001096938 us-gaap:SubsequentEventMember 2023-08-01 0001096938 us-gaap:SubsequentEventMember 2023-08-01 2023-10-01 0001096938 ueec:CeoAndCmaMember 2023-01-01 2023-06-30 0001096938 ueec:InstallmentThreeMember 2022-06-01 2022-06-15 0001096938 ueec:InstallmentFourMember 2022-06-01 2022-06-15 0001096938 ueec:InstallmentTwoMember 2022-06-01 2022-06-15 0001096938 2022-06-01 2022-06-15 0001096938 ueec:InstallmentOneMember 2022-06-01 2022-06-15 0001096938 ueec:ConsultantMember 2022-01-01 2022-06-30 0001096938 ueec:LegalCounselsMember 2022-01-01 2022-06-30 0001096938 ueec:ConsultantAgreementMember 2022-01-01 2022-06-30 0001096938 ueec:WhiteLionCapitalMember 2023-01-01 2023-06-30 0001096938 ueec:ShareIssuancesMember 2023-01-01 2023-06-30 0001096938 ueec:ShareIssuancesTwentyTwentyOneAndTwentyTwentyTwoMember 2023-01-01 2023-06-30 0001096938 us-gaap:SettledLitigationMember 2022-01-01 2022-06-30 0001096938 ueec:ShareIssuancesMember 2022-01-01 2022-06-30 0001096938 ueec:NonAffiliatedInvestorMember us-gaap:PrivatePlacementMember 2022-01-01 2022-06-30 0001096938 ueec:CommonStocksMember 2022-01-01 2022-06-30 0001096938 us-gaap:ConvertibleNotesPayableMember 2023-04-01 2023-06-30 0001096938 ueec:EquityTransactionsMember 2023-01-01 2023-06-30 0001096938 ueec:EquityTransactionsMember 2023-06-30 0001096938 2022-01-01 2022-12-31 0001096938 ueec:LoansPayableRelatedPartiesMember 2022-12-31 0001096938 ueec:LoansPayableRelatedPartiesMember 2023-06-30 0001096938 ueec:RelatedPartiesMember 2022-12-31 0001096938 ueec:RelatedPartiesMember 2023-06-30 0001096938 ueec:OfficersAndDirectorsMember 2023-06-30 0001096938 ueec:OfficersAndDirectorsMember 2022-12-31 0001096938 ueec:LoansPayableRelatedPartiesMember 2022-01-01 2022-06-30 0001096938 ueec:LoansPayableRelatedPartiesMember 2023-04-01 2023-06-30 0001096938 ueec:LoansPayableRelatedPartiesMember 2023-01-01 2023-06-30 0001096938 ueec:OfficersAndDirectorsMember 2022-01-01 2022-12-31 0001096938 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-06-30 0001096938 ueec:ConvertibleNotesPayableRelatedPartiesMember 2023-01-01 2023-06-30 0001096938 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001096938 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001096938 us-gaap:RetainedEarningsMember 2023-06-30 0001096938 ueec:SubscriptionReceivableMember 2023-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001096938 us-gaap:CommonStockMember 2023-06-30 0001096938 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001096938 ueec:SubscriptionReceivableMember 2023-04-01 2023-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001096938 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001096938 2023-03-31 0001096938 us-gaap:RetainedEarningsMember 2023-03-31 0001096938 ueec:SubscriptionReceivableMember 2023-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001096938 us-gaap:CommonStockMember 2023-03-31 0001096938 2023-01-01 2023-03-31 0001096938 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001096938 ueec:SubscriptionReceivableMember 2023-01-01 2023-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001096938 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001096938 us-gaap:RetainedEarningsMember 2022-12-31 0001096938 ueec:SubscriptionReceivableMember 2022-12-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001096938 us-gaap:CommonStockMember 2022-12-31 0001096938 2022-06-30 0001096938 us-gaap:RetainedEarningsMember 2022-06-30 0001096938 ueec:SubscriptionReceivableMember 2022-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001096938 us-gaap:CommonStockMember 2022-06-30 0001096938 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001096938 ueec:SubscriptionReceivableMember 2022-04-01 2022-06-30 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001096938 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001096938 2022-03-31 0001096938 us-gaap:RetainedEarningsMember 2022-03-31 0001096938 ueec:SubscriptionReceivableMember 2022-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001096938 us-gaap:CommonStockMember 2022-03-31 0001096938 2022-01-01 2022-03-31 0001096938 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001096938 ueec:SubscriptionReceivableMember 2022-01-01 2022-03-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001096938 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001096938 2021-12-31 0001096938 us-gaap:RetainedEarningsMember 2021-12-31 0001096938 ueec:SubscriptionReceivableMember 2021-12-31 0001096938 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001096938 us-gaap:CommonStockMember 2021-12-31 0001096938 2022-01-01 2022-06-30 0001096938 2022-04-01 2022-06-30 0001096938 2023-04-01 2023-06-30 0001096938 ueec:SeriesAConvertiblePreferredStockMember 2022-12-31 0001096938 ueec:SeriesAConvertiblePreferredStockMember 2023-06-30 0001096938 2022-12-31 0001096938 2023-06-30 0001096938 2023-08-09 iso4217:USD shares iso4217:USD shares pure 0001096938 false --12-31 Q2 2023

0.001

300000000

1000000

241123222

230871034

2025

0 0 47665000 10-Q true 2023-06-30 false 000-27781 UNITED HEALTH PRODUCTS, INC. NV 84-1517723 526 Commerce Circle Suite #120 Mesquite NV 89027 475 755-1005 Yes Yes Non-accelerated Filer true false false 241123222

133601

13377

33598

34730

7563

22932

174762

71039

132281 243039 89575 0

2850

34425

36450

433893

350528

1116562

1255232

174040

172579

150000

300000

22208

10000

9136

4000

201935

196177

490221 478331

2168966

2415455

67367

2236333

2415455

0.001

1000000

0.001

300000000

241123222

230871034

241123

230871

311820

50550

74009817

71830695

-75741560

-74075943

-1802440

-2064927

433893

350528

370343

607186

1205642

1509332

105113

147611

323789

199966

475456

754797

1529431

1709298

-475456

-754797

-1529431

-1709298

8329

205

16656

285

19532 11535 38998 20343

-19594

-112500

-80532

-113375

-47455

-124240

-136186

-134003

-522911

-879037

-1665617

-1843301

-0.00 -0.00 -0.01 -0.01 238269719 229737399 235376226 229257932

228667229

228667

71017881

-72388442

-1141894

20000

10180

10200

184028

184

77108

77292

6252 6 3995 0 0 4001

-964264

228877509

228877

71109164

-73352706

-2014665

200000

200

95800

96000

425000 425 203575 0 0 204000 20000 200 95800 0 0 96000 425000 425 203575 0 0 204000 -250000 -250 250 0 0 0

-879037

229877509

229877

71708164

-74231743

-2293702

230871034

230871

71830695

-50550

-74075943

-2064927

2535000

2535

522770

50550

575855

637500 638 168300 0 0 168938 300000 300 79200 0 0 79500 400000 400 71317 -71717 0 0 0 -55371 0 0 -55371 1850000 1850 460650 0 0 462500

-1142706

236593534

236594

73077561

-71717

-75218649

-1976211

2450000

2450

501558

71717

575725

567188 566 101527 0 0 102093 412500 413 73838 0 0 74251 1100000 1100 310720 -311820 0 0 0 -55387 0 0 -55387

-522911

241123222

241123

74009817

-311820

-75741560

-1802440

1665617

1843301

310200

2025

17648

-80532

-113375

462500 0

1132

-15369

9206

-12670

500774

229711

146944

150000 -380000

-1019370

-399189

40500

-2850 0

-2850

-40500

383275

9136

36261

1151580

77292

1142444

424306

120224

-15383

13377

21799

133601

6416

285

0 250 311820 0 110758 0 92425 0 218250 127500 10000 0 126000 63126 0 100000

Note 1. Organization and Basis of Preparation United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. The Company in the process of seeking regulatory approval to sell our HemoStyp product line into the U.S. Class III and European Union CE Mark surgical markets. The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 28, 2023. In the opinion of management, all adjustments, which are of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period, have been included.

Note 2. Significant Accounting Policies Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Cash and Cash Equivalents The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ. Fair Value Measurements Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business. Trade Accounts Receivable and Concentration Risk We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.There were no provisions for doubtful accounts recorded at June 30, 2023 and December 31, 2022. The Company recorded $0 in bad debt expense for the three and six month periods ended June 30, 2023 and 2022. Inventory Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of work-in process. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33,598</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">34,730</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total inventory</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">33,598</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">34,730</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the six months ended June 30, 2023 and 2022, the Company determined that $0 needed to be impaired and written-off. During the six months ended June 30, 2023, the Company used $1,132 of inventory as samples for its FDA testing and recorded it to research and development on the Statement of Operations. Stock Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Stock-based compensation expense for employees and non-employees is measured at the grant date fair value. Stock-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period. Per Share Information Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three and six months ended June 30, 2023 and 2022 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of June 30, 2023 included 47,665,000 of restricted stock units, 3,552,376 shares for convertible notes payable – related parties and 1,406,300 shares for convertible notes payable. The total potential common shares as of June 30, 2022 included 30,915,000 of restricted stock units. Patents Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. Accumulated amortization as of June 30, 2023 and December 31, 2022 was $6,075 and $4,050, respectively. Amortization expense for the six months ended June 30, 2023 and 2022 was $2,025, respectively. Future Amortization Expense <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Year</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 (remaining)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,025</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">34,425</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Impairment of Long-lived Assets The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended June 30, 2023 and 2022, the Company determined no impairment was required. Deferred Offering Costs Deferred offering costs represent specific incremental costs directly attributable to the offering of securities. The deferred offering costs are recorded as an offset to additional paid-in capital and charged against the proceeds received. Advertising and Marketing Costs Advertising and marketing expenses are expensed as incurred. The Company incurred $57,536 and $55,000 in advertising and marketing costs during the six months ended June 30, 2023 and 2022, respectively. Research and Development The Company charges research and development costs to expense when incurred. The Company incurred $323,789 and $199,966 in research and development expenses during the six months ended June 30, 2023 and 2022, respectively. Leases The Company follows the provisions of ASC 842, and records right-of-use ("ROU") assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less. New Accounting Pronouncements The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these matters, there is substantial doubt about the Company’s ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its HemoStyp product by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer. No discounts are currently offered by the Company. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.

We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers that are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credit issued.There were no provisions for doubtful accounts recorded at June 30, 2023 and December 31, 2022. The Company recorded $0 in bad debt expense for the three and six month periods ended June 30, 2023 and 2022.

Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of work-in process. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33,598</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">34,730</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total inventory</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">33,598</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">34,730</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the six months ended June 30, 2023 and 2022, the Company determined that $0 needed to be impaired and written-off. During the six months ended June 30, 2023, the Company used $1,132 of inventory as samples for its FDA testing and recorded it to research and development on the Statement of Operations.

33598

34730

33598

34730

1132

The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation-Stock Compensation. Stock-based compensation expense for employees and non-employees is measured at the grant date fair value. Stock-based compensation for all stock-based awards to employees and directors is recognized as an expense over the requisite service period, which is generally the vesting period.

Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred net losses for the three and six months ended June 30, 2023 and 2022 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of June 30, 2023 included 47,665,000 of restricted stock units, 3,552,376 shares for convertible notes payable – related parties and 1,406,300 shares for convertible notes payable. The total potential common shares as of June 30, 2022 included 30,915,000 of restricted stock units.

47665000

3552376

1406300

30915000

Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. Accumulated amortization as of June 30, 2023 and December 31, 2022 was $6,075 and $4,050, respectively. Amortization expense for the six months ended June 30, 2023 and 2022 was $2,025, respectively. Future Amortization Expense <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Year</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 (remaining)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,025</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">34,425</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

straight-line basis over the estimated useful life of 10 years 6075 4050

2025

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Year</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 (remaining)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,025</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,050</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">34,425</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

2025

4050

16200

34425

The Company applies the provisions of ASC 360, Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the six months ended June 30, 2023 and 2022, the Company determined no impairment was required.

Deferred offering costs represent specific incremental costs directly attributable to the offering of securities. The deferred offering costs are recorded as an offset to additional paid-in capital and charged against the proceeds received.

Advertising and marketing expenses are expensed as incurred. The Company incurred $57,536 and $55,000 in advertising and marketing costs during the six months ended June 30, 2023 and 2022, respectively.

57536

55000

The Company charges research and development costs to expense when incurred. The Company incurred $323,789 and $199,966 in research and development expenses during the six months ended June 30, 2023 and 2022, respectively.

323789

199966

The Company follows the provisions of ASC 842, and records right-of-use ("ROU") assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

The Company considers all new pronouncements and management has determined that there have been no recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Note 3. Related Party Transactions Convertible notes payable - related parties During the year ended December 31, 2022, Brian Thom, the Company’s Chief Executive Officer, converted $372,000 of a loan payable balance to a convertible note payable. The unpaid accrued interest on the loan payable was transferred to the convertible note payable. The note has an interest rate of 10%, an original issue discount (“OID”) of 7% and has a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $28,000 of a debt discount related to the OID. As of June 30, 2023 and December 31, 2022, the remaining unamortized debt discount was $7,578 and $16,998, respectively. Accrued interest associated with the note was $55,592 and $33,897 as of June 30, 2023 and December 31, 2022, respectively. During the year ended December 31, 2022, Robert Denser, a Director of the Company, loaned the Company $93,000 through a convertible note. The note has an interest rate of 10%, an OID of 7% and has a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $7,000 of a debt discount related to the OID. As of June 30, 2023 and December 31, 2022, the remaining unamortized debt discount was $2,201 and $4,671, respectively. Accrued interest associated with the note was $9,236 and $4,034 as of June 30, 2023 and December 31, 2022, respectively. Interest expense – related party on the above convertible notes payable was $19,426 (including $5,978 of debt discount amortization related to the OID) and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $38,786 (including $11,890 of debt discount amortization related to the OID) and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest – related party due to these convertible notes was $64,828 and $37,931, as of June 30, 2023 and December 31, 2022, respectively. Loans payable – related parties During the year ended December 31, 2022, Kristofer Heaton, the Principal Financial Officer, loaned the Company $4,000 to pay for operating expenses. As of June 30, 2023 and December 31, 2022, $4,000 in principal was owed on the loan payable. The loan has an interest rate of 10% and is due on demand. Interest expense – related party on the above loans was $106 and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $212 and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest – related party as of June 30, 2023 and December 31, 2022 was $436 and $224, respectively. Accrued liabilities – related parties As of June 30, 2023 and December 31, 2022, $108,776 and $127,500 of accrued compensation and reimbursable expenses was due to the Company’s officers and management, respectively. Equity transactions During the six months ended June 30, 2023, the Company issued 1,204,688 shares of common stock with a fair value of $271,031 to its officers and management for $218,250 of accrued compensation (see Note 6).

372000

0.10 0.07 December 31, 2023 0.35

0.35

28000

7578

16998

55592

33897

93000

0.10

0.07 December 31, 2023 0.35

0.35

7000

2201

4671

9236

4034

19426

5978

38786

64828

37931

4000

0.10

106 212 0

436

224

108776

127500

1204688

271031

218250

Note 4. Promissory Note Payable During the year ended December 31, 2022, the Company had entered into a $100,000 promissory note and had a principal balance of $9,136 and accrued interest of $0 as of December 31, 2022. The note accrued interest at 1% and requires monthly payments of $9,136 until the balance was paid in full. During the six months ended June 30, 2023, the Company paid the remaining principal balance of $9,136. As of June 30, 2023, the principal balance and accrued interest was $0. During the six months ended June 30, 2023, $10,000 of accounts payable and accrued liabilities were paid on behalf of the Company. The Company entered into a note payable for the $10,000 payment. The note payable has an interest rate of 5% and has a maturity date of December 31, 2023. Interest expense on the above loans was $125 and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $250 and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest as of June 30, 2023 and December 31, 2022 was $250 and $0, respectively.

100000

9136

0.01

9136 9136

10000

0.05

December 31, 2023

125

250

250 0 Note 5. Convertible Notes During the year ended December 31, 2022, the Company issued a $93,000 convertible note and a $99,975 convertible note and received total proceeds of $192,975. The notes have an interest rate of 10%, an OID of 7% and have a maturity date of December 31, 2023. The notes are convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $14,525 of a debt discount related to the OID. As of June 30, 2023 and December 31, 2022, the remaining unamortized debt discount was $5,565 and $11,323, respectively. Interest expense on the above convertible notes payable was $8,204 (including $2,895 of debt discount amortization related to the OID) and $0 during the three months ended June 30, 2023 and 2022, respectively. Interest expense was $16,406 (including $5,758 of debt discount amortization related to the OID) and $0 during the six months ended June 30, 2023 and 2022, respectively. Accrued interest as of June 30, 2023 and December 31, 2022 was $16,102 and $5,454, respectively, and has been recorded in accrued liabilities on the balance sheet. 93000

99975

192975 0.10 0.07 December 31, 2023 0.35

0.35

14525

5565

11323

8204

2895 0 16406 5758 0 16102 5454

Note 6. Issuances of Securities Share issuances 2022 During the six months ended June 30, 2022, the Company had the following common stock transactions: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">184,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $77,292.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">206,252 shares of commons stock with a fair value of $100,001 were issued to various consultants to settle $63,126 of accrued liabilities resulting in a loss on settlement of debt of $36,875.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">200,000 shares of common stock with a fair value of $96,000 were issued to consultants for services.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">425,000 shares of common stock were issued to settle $127,500 of accrued liabilities – related party resulting in a loss of settlement of debt of $76,500.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">425,000 shares of common stock with a fair value of $204,000 were issued to officers and a former officer of the Company for services.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">250,000 shares of common stock were cancelled reducing common stock by $250 and increasing additional paid-in capital by the same.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">20,000 shares of common stock with a fair value of $10,200 were issued for legal services.</td></tr></tbody></table>Share issuances 2023 During the six months ended June 30, 2023, the Company had the following common stock transactions: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">1,204,688 shares of common stock with a fair value of $271,031 were issued to officers and management of the Company to settle $218,250 of accrued liabilities (see Note 3) resulting in a loss on settlement of debt of $52,781.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">712,500 shares of common stock with a fair value of $153,751 were issued to consultants to settle $126,000 of accrued liabilities resulting in a loss on debt settlement of $27,751.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">5,385,000 shares of common stock were sold for $1,151,580, net of legal and administrative fees of $6,600 and which included a payment of $50,550 for a subscription receivable, under the Company’s common stock purchase agreement with White Lion. White Lion also purchased 1,100,000 shares for proceeds of $311,820 which were received in July 2023 and is shown as a subscription receivable in the balance sheet as of June 30, 2023.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">1,850,000 shares of common stock with a fair value of $462,500 were issued to settle litigation (see Note 8).</td></tr></tbody></table> Restricted stock units As of June 30, 2023 and December, 31, 2022, the Company has granted a total of 47,665,000 restricted stock units (RSU). The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur and as of June 30, 2023, there was $25,313,630 of unrecognized compensation cost related to unvested restricted stock unit awards. Activity related to our restricted stock units during the three months ended June 30, 2023 was as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Weighted </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Grant </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Number of </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Date Fair </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Units </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Value </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total awards outstanding at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,665,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.54</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Units granted </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Units Exercised/Released </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Units Cancelled/Forfeited </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total awards outstanding at June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">47,665,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.54</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

184028

77292

206252

100001 63126

36875

200000

96000

425000

127500

76500

425000

204000 250000 250

20000

10200

1204688

271031

218250

52781

712500

153751 126000

27751

5385000

1151580

6600

50550

1100000

311820

1850000 462500 47665000

25313630

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Weighted </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Grant </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Number of </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Date Fair </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Units </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Value </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total awards outstanding at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">47,665,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.54</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Units granted </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Units Exercised/Released </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Units Cancelled/Forfeited </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total awards outstanding at June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">47,665,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.54</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

47665000

0.54

47665000

0.54

Note 7. Accrued Litigation Settlement On June 15, 2022, the Security and Exchange Commission’s (SEC) investigation of the Company, initially reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, was settled through the filing of a consent judgment without the Company admitting or denying the SEC’s allegations. As part of the settlement, the Company is required to pay a civil penalty of $450,000, payable in four installments as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:7%;vertical-align:top;">·</td><td style="vertical-align:top;">$50,000 upon the entry of the judgment;</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">$100,000 within 90 days of the entry of the judgment;</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">$150,000 within 180 days of the entry of the judgment; and</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">$150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961</td></tr></tbody></table> The Company has made total payments of $300,000 towards the civil penalty through June 30, 2023. As of June 30, 2023 and December 31, 2022, the remaining balance was $150,000 and $300,000, respectively. The Company and the SEC have agreed upon an amended schedule of payments for the remaining balance owed under the settlement (see Note 10).

450000

50000

100000

150000

300000

150000

300000

Note 8. Litigation Effective as of March 31, 2023, a 2018 lawsuit filed by Philip Forman, against the Company and its former CEO relating to the validity of a June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company and claims for compensation on termination of his employment was settled. In the settlement, as full and complete consideration, the Company issued to Mr. Forman 1,850,000 shares of common stock of the Company with a fair value of $462,500.

1850000

462500

Note 9. Leases In May 2023, the Company entered into 36-month operating lease, which provides for approximately 1,800 square feet of office space, that commenced on June 1, 2023 and ends on May 31, 2026. The lease required a $2,850 security deposit and monthly lease payments are $2,850 the first year of the lease, $2,964 the second year and $3,082 the third year. Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. On the commencement date of the lease, the Company recorded $92,425 related to the ROU asset and lease liability. The components of lease expense and supplemental cash flow information related to the lease for the period are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six Months EndedJune 30, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Lease Cost</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Operating lease cost (included in general and administrative in the Company’s statement of operations)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,850</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other Information</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,850</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average remaining lease term – operating leases (in years)</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">2.92 years</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Average discount rate – operating lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table> The supplemental balance sheet information related to leases for the period is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">At June 30, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">At December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Operating leases</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Remaining right-of-use assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">89,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td> </td><td> </td><td class="ffcell"> </td><td> </td><td> </td><td> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Short-term operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,208</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Long-term operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">67,367</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">89,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Maturities of the Company’s undiscounted lease liabilities are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year Ending</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operating Leases</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 (Remaining)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,998</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,394</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,410</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103,902</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest/present value discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,327 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Present value of lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">89,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

the Company entered into 36-month operating lease, which provides for approximately 1,800 square feet of office space, that commenced on June 1, 2023 and ends on May 31, 2026. The lease required a $2,850 security deposit and monthly lease payments are $2,850 the first year of the lease, $2,964 the second year and $3,082 the third year 92425

2850

2850 P2Y11M1D

0.10

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">At June 30, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">At December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Operating leases</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Remaining right-of-use assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">89,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td> </td><td> </td><td class="ffcell"> </td><td> </td><td> </td><td> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Short-term operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,208</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Long-term operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">67,367</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total operating lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">89,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 89575 0

22208

67367

89575

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year Ending</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operating Leases</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 (Remaining)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,998</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,394</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,410</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total lease payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103,902</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Imputed interest/present value discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,327 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Present value of lease liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">89,575</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

17100

34998

36394

15410

103902

14327

89575

Note 10. Subsequent Events The Company has evaluated events from June 30, 2023, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed except as follows: The Company has proposed an amended installment payment plan to the SEC related to its civil penalty (see Note 7). The proposed payment plan calls for the Company to make three $50,000 payments with payments due on August 1, 2023, September 1, 2023 and October 1, 2023 with any remaining principal plus outstanding post-judgement interest to be paid on November 1, 2023. The $50,000 due on August 1, 2023 was paid by the Company.

50000 50000 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 91 245 1 false 28 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://unitedhealthproductsinc.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Balance Sheets Sheet http://unitedhealthproductsinc.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Condensed Statement of Stockholders Equity (Unaudited) Sheet http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited Condensed Statement of Stockholders Equity (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Organization and Basis of Preparation Sheet http://unitedhealthproductsinc.com/role/OrganizationAndBasisOfPreparation Organization and Basis of Preparation Notes 7 false false R8.htm 000008 - Disclosure - Significant Accounting Policies Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Related Party Transactions Sheet http://unitedhealthproductsinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 000010 - Disclosure - Promissory Note Payable Sheet http://unitedhealthproductsinc.com/role/PromissoryNotePayable Promissory Note Payable Notes 10 false false R11.htm 000011 - Disclosure - Convertible Notes Notes http://unitedhealthproductsinc.com/role/ConvertibleNotes Convertible Notes Notes 11 false false R12.htm 000012 - Disclosure - Issuances of Securities Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecurities Issuances of Securities Notes 12 false false R13.htm 000013 - Disclosure - Accrued Litigation Settlement Sheet http://unitedhealthproductsinc.com/role/AccruedLitigationSettlement Accrued Litigation Settlement Notes 13 false false R14.htm 000014 - Disclosure - Litigation Sheet http://unitedhealthproductsinc.com/role/Litigation Litigation Notes 14 false false R15.htm 000015 - Disclosure - Leases Sheet http://unitedhealthproductsinc.com/role/Leases Leases Notes 15 false false R16.htm 000016 - Disclosure - Subsequent Event Sheet http://unitedhealthproductsinc.com/role/SubsequentEvent Subsequent Event Notes 16 false false R17.htm 000017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies 17 false false R18.htm 000018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies 18 false false R19.htm 000019 - Disclosure - Issuances of Securities (Tables) Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables Issuances of Securities (Tables) Tables http://unitedhealthproductsinc.com/role/IssuancesOfSecurities 19 false false R20.htm 000020 - Disclosure - Leases (Tables) Sheet http://unitedhealthproductsinc.com/role/LeasesTables Leases (Tables) Tables http://unitedhealthproductsinc.com/role/Leases 20 false false R21.htm 000021 - Disclosure - Significant Accounting Policies (Details) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables 21 false false R22.htm 000022 - Disclosure - Significant Accounting Policies (Details 1) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1 Significant Accounting Policies (Details 1) Details http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables 22 false false R23.htm 000023 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables 23 false false R24.htm 000024 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://unitedhealthproductsinc.com/role/RelatedPartyTransactions 24 false false R25.htm 000025 - Disclosure - Promissory Note Payable (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative Promissory Note Payable (Details Narrative) Details http://unitedhealthproductsinc.com/role/PromissoryNotePayable 25 false false R26.htm 000026 - Disclosure - Convertible Notes (Details Narrative) Notes http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative Convertible Notes (Details Narrative) Details http://unitedhealthproductsinc.com/role/ConvertibleNotes 26 false false R27.htm 000027 - Disclosure - Issuances of Securities (Details) Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails Issuances of Securities (Details) Details http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables 27 false false R28.htm 000028 - Disclosure - Issuances of Securities (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative Issuances of Securities (Details Narrative) Details http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables 28 false false R29.htm 000029 - Disclosure - Accrued Litigation Settlement (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative Accrued Litigation Settlement (Details Narrative) Details http://unitedhealthproductsinc.com/role/AccruedLitigationSettlement 29 false false R30.htm 000030 - Disclosure - Litigation (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative Litigation (Details Narrative) Details http://unitedhealthproductsinc.com/role/Litigation 30 false false R31.htm 000031 - Disclosure - Leases (Details) Sheet http://unitedhealthproductsinc.com/role/LeasesDetails Leases (Details) Details http://unitedhealthproductsinc.com/role/LeasesTables 31 false false R32.htm 000032 - Disclosure - Leases (Details 1) Sheet http://unitedhealthproductsinc.com/role/LeasesDetails1 Leases (Details 1) Details http://unitedhealthproductsinc.com/role/LeasesTables 32 false false R33.htm 000033 - Disclosure - Leases (Details 2) Sheet http://unitedhealthproductsinc.com/role/LeasesDetails2 Leases (Details 2) Details http://unitedhealthproductsinc.com/role/LeasesTables 33 false false R34.htm 000034 - Disclosure - Leases (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://unitedhealthproductsinc.com/role/LeasesTables 34 false false R35.htm 000035 - Disclosure - Subsequent Events (Details Narrative) Sheet http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://unitedhealthproductsinc.com/role/SubsequentEvent 35 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 15 fact(s) appearing in ix:hidden were eligible for transformation: ueec:AccountsPayableAndAccruedExpensesPaidPromissoryNotePayable, ueec:ImpairedAndWrittenOff, ueec:RestrictedStockUnitsGranted, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:ExplorationExpense, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProvisionForDoubtfulAccounts - ueec_10q.htm 1 ueec_10q.htm ueec-20230630.xsd ueec-20230630_cal.xml ueec-20230630_def.xml ueec-20230630_lab.xml ueec-20230630_pre.xml ueec_ex311.htm ueec_ex312.htm ueec_ex321.htm ueec_ex322.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ueec_10q.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 370, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 91, "dts": { "calculationLink": { "local": [ "ueec-20230630_cal.xml" ] }, "definitionLink": { "local": [ "ueec-20230630_def.xml" ] }, "inline": { "local": [ "ueec_10q.htm" ] }, "labelLink": { "local": [ "ueec-20230630_lab.xml" ] }, "presentationLink": { "local": [ "ueec-20230630_pre.xml" ] }, "schema": { "local": [ "ueec-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 333, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 12, "http://unitedhealthproductsinc.com/20230630": 3, "http://xbrl.sec.gov/dei/2023": 5, "total": 20 }, "keyCustom": 83, "keyStandard": 162, "memberCustom": 20, "memberStandard": 8, "nsprefix": "ueec", "nsuri": "http://unitedhealthproductsinc.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://unitedhealthproductsinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Promissory Note Payable", "menuCat": "Notes", "order": "10", "role": "http://unitedhealthproductsinc.com/role/PromissoryNotePayable", "shortName": "Promissory Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:ConvertibleNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Convertible Notes", "menuCat": "Notes", "order": "11", "role": "http://unitedhealthproductsinc.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:ConvertibleNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Issuances of Securities", "menuCat": "Notes", "order": "12", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecurities", "shortName": "Issuances of Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:AccruedLitigationSettlementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Accrued Litigation Settlement", "menuCat": "Notes", "order": "13", "role": "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlement", "shortName": "Accrued Litigation Settlement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:AccruedLitigationSettlementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Litigation", "menuCat": "Notes", "order": "14", "role": "http://unitedhealthproductsinc.com/role/Litigation", "shortName": "Litigation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Leases", "menuCat": "Notes", "order": "15", "role": "http://unitedhealthproductsinc.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Subsequent Event", "menuCat": "Notes", "order": "16", "role": "http://unitedhealthproductsinc.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:GoingConcernPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "17", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:GoingConcernPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "18", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Issuances of Securities (Tables)", "menuCat": "Tables", "order": "19", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables", "shortName": "Issuances of Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Condensed Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "20", "role": "http://unitedhealthproductsinc.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Significant Accounting Policies (Details)", "menuCat": "Details", "order": "21", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Significant Accounting Policies (Details 1)", "menuCat": "Details", "order": "22", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1", "shortName": "Significant Accounting Policies (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ueec:AccumulatedAmortization", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "ueec:AccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Promissory Note Payable (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative", "shortName": "Promissory Note Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ueec:ConvertibleNotesDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ueec:AccruedInterestLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Convertible Notes (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "shortName": "Convertible Notes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ueec:ConvertibleNotesDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "ueec:AccruedInterestLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Issuances of Securities (Details)", "menuCat": "Details", "order": "27", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails", "shortName": "Issuances of Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ueec:RepurchaseOfSharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Issuances of Securities (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "shortName": "Issuances of Securities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ueec:RepurchaseOfSharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ueec:AccruedLitigationSettlementDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-06-01to2022-06-15", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Accrued Litigation Settlement (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative", "shortName": "Accrued Litigation Settlement (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ueec:AccruedLitigationSettlementDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-06-01to2022-06-15", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Condensed Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-04-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Litigation (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "shortName": "Litigation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30_ueec_CeoAndCmaMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Leases (Details)", "menuCat": "Details", "order": "31", "role": "http://unitedhealthproductsinc.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ueec:ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ueec:RemainingOperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Leases (Details 1)", "menuCat": "Details", "order": "32", "role": "http://unitedhealthproductsinc.com/role/LeasesDetails1", "shortName": "Leases (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ueec:ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "ueec:RemainingOperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ueec:ScheduleOfUndiscountedLeaseLiabilitiesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Leases (Details 2)", "menuCat": "Details", "order": "33", "role": "http://unitedhealthproductsinc.com/role/LeasesDetails2", "shortName": "Leases (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ueec:ScheduleOfUndiscountedLeaseLiabilitiesTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:LeasesDescriptionOfSecurityDepositeAndMonthlyPayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Leases (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://unitedhealthproductsinc.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ueec:LeasesDescriptionOfSecurityDepositeAndMonthlyPayments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-08-01to2023-10-01_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "ueec:PaymentDueForCallPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-08-01to2023-10-01_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "ueec:PaymentDueForCallPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Condensed Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Condensed Statement of Stockholders Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "shortName": "Condensed Statement of Stockholders Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2022-01-01to2022-03-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Organization and Basis of Preparation", "menuCat": "Notes", "order": "7", "role": "http://unitedhealthproductsinc.com/role/OrganizationAndBasisOfPreparation", "shortName": "Organization and Basis of Preparation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "9", "role": "http://unitedhealthproductsinc.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ueec_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r445", "r482" ], "lang": { "en-us": { "role": { "label": "Title Of Individual Axis" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_AccountsPayableAndAccruedExpensesPaidNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses paid with promissory note payable" } } }, "localname": "AccountsPayableAndAccruedExpensesPaidNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_AccountsPayableAndAccruedExpensesPaidPromissoryNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses on promissory note payable" } } }, "localname": "AccountsPayableAndAccruedExpensesPaidPromissoryNotePayable", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_AccruedInterestLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Interest" } } }, "localname": "AccruedInterestLiability", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_AccruedInterestNotesPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest note" } } }, "localname": "AccruedInterestNotesPayables", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_AccruedLitigationSettlementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Accrued Litigation Settlement]", "verboseLabel": "Accrued Litigation Settlement" } } }, "localname": "AccruedLitigationSettlementDisclosureTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlement" ], "xbrltype": "textBlockItemType" }, "ueec_AccruedLitigationSettlementPaidNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued litigation settlement paid with loan payable" } } }, "localname": "AccruedLitigationSettlementPaidNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_AccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accumulated amortization" } } }, "localname": "AccumulatedAmortization", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_AmortizationOfDeferredOfferingCostNonCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Amortization of deferred offering costs]", "verboseLabel": "Amortization of deferred offering costs" } } }, "localname": "AmortizationOfDeferredOfferingCostNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_AmortizationOfDeferredOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization of deferred offering costs" } } }, "localname": "AmortizationOfDeferredOfferingCosts", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CancellationOfCommonStockAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cancellation of common stock, amount" } } }, "localname": "CancellationOfCommonStockAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CancellationOfCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancellation of common stock, shares" } } }, "localname": "CancellationOfCommonStockShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CancellationOfStockNonCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cancellation of common stock" } } }, "localname": "CancellationOfStockNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CashPaidForLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2023" } } }, "localname": "CashPaidForLeaseLiabilities", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "ueec_CeoAndCmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Chief Executive Officer and Chief Medical Advisor [Member]" } } }, "localname": "CeoAndCmaMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_CommonStockIssuedForAStockSubscriptionReceivableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for a stock subscription receivable, amount" } } }, "localname": "CommonStockIssuedForAStockSubscriptionReceivableAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedForAStockSubscriptionReceivableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for a stock subscription receivable, shares" } } }, "localname": "CommonStockIssuedForAStockSubscriptionReceivableShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedForLitigationSettlementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for litigation settlement, amount" } } }, "localname": "CommonStockIssuedForLitigationSettlementAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedForLitigationSettlementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for litigation settlement, shares", "verboseLabel": "Common stock issued for litigation settlement, shares" } } }, "localname": "CommonStockIssuedForLitigationSettlementShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedForSubscriptionReceivableNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for subscription receivable" } } }, "localname": "CommonStockIssuedForSubscriptionReceivableNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accounts payable and accrued liabilities, amount" } } }, "localname": "CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesRelatedPartyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accounts payable and accrued liabilities - related party, amount" } } }, "localname": "CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesRelatedPartyAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle accounts payable and accrued liabilities - related party, shares" } } }, "localname": "CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesRelatedPartyShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle accounts payable and accrued liabilities, shares" } } }, "localname": "CommonStockIssuedToSettleAccountsPayableAndAccruedLiabilitiesShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities, amount" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities - related party, amount" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities - related party" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities - related party, shares" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockIssuedToSettleAccruedLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued to settle accrued liabilities, shares" } } }, "localname": "CommonStockIssuedToSettleAccruedLiabilitiesShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_CommonStockSharesCancellations": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares cancellations" } } }, "localname": "CommonStockSharesCancellations", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_CommonStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStocksMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_ConsultantAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultant Agreement [Member]" } } }, "localname": "ConsultantAgreementMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_ConversionOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion Of Common Stock" } } }, "localname": "ConversionOfCommonStock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ueec_ConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Conversion Of Common Stock]", "verboseLabel": "Conversion Of Common Stock" } } }, "localname": "ConversionPrice", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ueec_ConvertibleNoteCommonStockSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Per Share price" } } }, "localname": "ConvertibleNoteCommonStockSharePrice", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ueec_ConvertibleNoteInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Interest Rate", "verboseLabel": "Interest Rate" } } }, "localname": "ConvertibleNoteInterestRate", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ueec_ConvertibleNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes" } } }, "localname": "ConvertibleNotesAbstract", "nsuri": "http://unitedhealthproductsinc.com/20230630", "xbrltype": "stringItemType" }, "ueec_ConvertibleNotesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Convertible Notes]", "verboseLabel": "Convertible Notes" } } }, "localname": "ConvertibleNotesDisclosureTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "ueec_ConvertibleNotesPayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturity of convertible notes payable" } } }, "localname": "ConvertibleNotesPayableDescription", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_ConvertibleNotesPayableRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Related Parties [Member]" } } }, "localname": "ConvertibleNotesPayableRelatedPartiesMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_ConvertibleNotesPayableRelatedPartyNetOfDebtDiscountCurrent": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible notes payable - related party, net of debt discount" } } }, "localname": "ConvertibleNotesPayableRelatedPartyNetOfDebtDiscountCurrent", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ueec_DebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Debt Discount" } } }, "localname": "DebtDiscount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_DebtDiscountAmortizationRelatedToOid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Debt discount amortization related to OID]", "verboseLabel": "Debt discount amortization related to OID" } } }, "localname": "DebtDiscountAmortizationRelatedToOid", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_DebtDiscountLoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Debt Discount]", "verboseLabel": "Debt Discount" } } }, "localname": "DebtDiscountLoanAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_DebtInstrumentsMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Maturity Date]", "verboseLabel": "Maturity Date" } } }, "localname": "DebtInstrumentsMaturityDate", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_DeferredOfferingCostsNonCurrent": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsNonCurrent", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ueec_DeferredOfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs" } } }, "localname": "DeferredOfferingCostsPolicyTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ueec_DescriptionOfPatent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of patent" } } }, "localname": "DescriptionOfPatent", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_DueFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loan To Company" } } }, "localname": "DueFromRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_EarningPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted" } } }, "localname": "EarningPerShareBasicAndDiluted", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "ueec_EquityTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity transactions [Member]" } } }, "localname": "EquityTransactionsMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_FairValueOfStockIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of common stock" } } }, "localname": "FairValueOfStockIssued", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ueec_ImpairedAndWrittenOff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Impaired and written-off" } } }, "localname": "ImpairedAndWrittenOff", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_IncreaseDecreaseInAccruedLiabilitiesRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued liabilities related party" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_IncreaseDecreaseInAccruedLitigationSettlement": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accrued litigation settlement]", "negatedLabel": "Accrued litigation settlement" } } }, "localname": "IncreaseDecreaseInAccruedLitigationSettlement", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_IncreasingAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increasing additional paid-in capital" } } }, "localname": "IncreasingAdditionalPaidInCapital", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityNonCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial recognition of operating lease right-of-use asset and operating lease liability" } } }, "localname": "InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityNonCash", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_InstallmentFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Installment Four [Member]" } } }, "localname": "InstallmentFourMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_InstallmentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Installment One [Member]" } } }, "localname": "InstallmentOneMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_InstallmentThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Installment Three [Member]" } } }, "localname": "InstallmentThreeMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_InstallmentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Installment Two [Member]" } } }, "localname": "InstallmentTwoMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_InterestExpenseConvertibleNotePayables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense convertible note" } } }, "localname": "InterestExpenseConvertibleNotePayables", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_InterestExpensesRelatedParty": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Interest expense - related party]", "negatedLabel": "Interest expense - related party" } } }, "localname": "InterestExpensesRelatedParty", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_InterestExpensesRelatedPartyConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense on convertible notes - related party" } } }, "localname": "InterestExpensesRelatedPartyConvertibleNotes", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_InterestExpensesRelatedPartyLoanPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest expense on related party" } } }, "localname": "InterestExpensesRelatedPartyLoanPayable", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_IssuanceOfCommonStockForServicesRelatedPartyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for services - related party, amount" } } }, "localname": "IssuanceOfCommonStockForServicesRelatedPartyAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_IssuanceOfCommonStockForServicesRelatedPartyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services - related party, shares" } } }, "localname": "IssuanceOfCommonStockForServicesRelatedPartyShares", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_IssuanceOfConvertibleNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance Of Convertible Note" } } }, "localname": "IssuanceOfConvertibleNote", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_IssueDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Original Issue Discount Rate]", "terseLabel": "Original Issue Discount Rate", "verboseLabel": "Original Issue Discount Rate" } } }, "localname": "IssueDiscountRate", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ueec_LeasesDescriptionOfSecurityDepositeAndMonthlyPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of leases security deposit and monthly lease payments" } } }, "localname": "LeasesDescriptionOfSecurityDepositeAndMonthlyPayments", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_LegalCounselsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Legal Counsels [Member]" } } }, "localname": "LegalCounselsMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_LitigationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation" } } }, "localname": "LitigationAbstract", "nsuri": "http://unitedhealthproductsinc.com/20230630", "xbrltype": "stringItemType" }, "ueec_LoansPayableRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable Related Parties [Member]" } } }, "localname": "LoansPayableRelatedPartiesMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_MaturityDateDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturity Date" } } }, "localname": "MaturityDateDuringPeriod", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_MaturityOfConvertibleNotesPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturity Of Convertible Notes Payable" } } }, "localname": "MaturityOfConvertibleNotesPayable", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ueec_NetLossPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per common share:" } } }, "localname": "NetLossPerCommonShareAbstract", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "ueec_NetPenaltyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total civil penalty amount" } } }, "localname": "NetPenaltyAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_NonAffiliatedInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Affiliated Investor [Member]" } } }, "localname": "NonAffiliatedInvestorMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_NotePayablePrincipleAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Promissory note" } } }, "localname": "NotePayablePrincipleAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_NotesPayableRemainingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Remaining principle balance on promissory note payable" } } }, "localname": "NotesPayableRemainingAmount", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers And Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_OperatingLeaseRightOfUseAssetNonCurrent": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetNonCurrent", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ueec_OriginalIssueDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Original Issue Discount Rate" } } }, "localname": "OriginalIssueDiscountRate", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ueec_PaymentDueForCallPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments due" } } }, "localname": "PaymentDueForCallPayment", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_PaymentsDueForCallPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments made by the company" } } }, "localname": "PaymentsDueForCallPayment", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_ProceedFromConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceed from convertible notes" } } }, "localname": "ProceedFromConvertibleNotes", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_RelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related parties [Member]" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_RemainingOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Remaining right-of-use assets" } } }, "localname": "RemainingOperatingLeaseRightOfUseAsset", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "ueec_RepurchaseOfSharesOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Repurchase common shares" } } }, "localname": "RepurchaseOfSharesOfCommonStock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_RestrictedStockUnitsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted stock units, granted" } } }, "localname": "RestrictedStockUnitsGranted", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ueec_RightOfUseOperatingLeaseAssetLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "ROU asset and lease liability" } } }, "localname": "RightOfUseOperatingLeaseAssetLiability", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of supplemental balance sheet information" } } }, "localname": "ScheduleOfBalanceSheetSupplementalDisclosuresTableTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ueec_ScheduleOfUndiscountedLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of undiscounted lease liabilities" } } }, "localname": "ScheduleOfUndiscountedLeaseLiabilitiesTableTextBlock", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ueec_SecurityDeposits": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Security deposit]", "verboseLabel": "Security deposit" } } }, "localname": "SecurityDeposits", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "ueec_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock Member" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ueec_ShareIssuancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Issuances [Member]" } } }, "localname": "ShareIssuancesMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_ShareIssuancesTwentyTwentyOneAndTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Issuances 2021 and 2022 [Member]" } } }, "localname": "ShareIssuancesTwentyTwentyOneAndTwentyTwentyTwoMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ueec_StockIssuedForLitigationSettlement": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock issued for litigation settlement", "verboseLabel": "Stock issued for litigation settlement" } } }, "localname": "StockIssuedForLitigationSettlement", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ueec_StockduringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "During Period" } } }, "localname": "StockduringPeriod", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "ueec_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Subscription Receivable]", "verboseLabel": "Subscription Receivable" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "ueec_TotalFutureLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "TotalFutureLeasePayments", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "ueec_UnitsExercisedRelease": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, units exercised/released" } } }, "localname": "UnitsExercisedRelease", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "perShareItemType" }, "ueec_WeightedAverageNumberOfSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstanding", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "ueec_WeightedAverageRemainingLeaseTermYears": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term - operating leases (in years)" } } }, "localname": "WeightedAverageRemainingLeaseTermYears", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "ueec_WhiteLionCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "White Lion Capital [Member]" } } }, "localname": "WhiteLionCapitalMember", "nsuri": "http://unitedhealthproductsinc.com/20230630", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingCurrent": { "auth_ref": [ "r8", "r33", "r34", "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to vendors that bear interest at either a stated or an imputed rate. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "AccountsPayableInterestBearingCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities - related parties" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r45", "r415", "r489" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "[Additional Paid in Capital]", "verboseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r232", "r233", "r234", "r315", "r441", "r442", "r443", "r480", "r492" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r4", "r29" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile net (loss) to Net Cash Used In Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdministrativeFeesExpense": { "auth_ref": [ "r38", "r355", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost.", "label": "Legal and administrative fees" } } }, "localname": "AdministrativeFeesExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r4", "r33", "r56", "r183" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potential antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r72", "r94", "r118", "r140", "r146", "r150", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r244", "r248", "r259", "r291", "r348", "r415", "r426", "r451", "r452", "r484" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r91", "r100", "r118", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r244", "r248", "r259", "r415", "r451", "r452", "r484" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r203", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r227", "r228", "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r41", "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Organization and Basis of Preparation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/OrganizationAndBasisOfPreparation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r20", "r59", "r114" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "periodStartLabel": "Cash and Cash Equivalents - Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r1", "r59" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Increase (decrease) in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash Investing & Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r88", "r95", "r96", "r97", "r118", "r131", "r132", "r134", "r135", "r138", "r139", "r158", "r165", "r167", "r168", "r169", "r172", "r173", "r188", "r189", "r191", "r194", "r200", "r259", "r306", "r307", "r308", "r309", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r335", "r357", "r379", "r398", "r399", "r400", "r401", "r402", "r431", "r439", "r444" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r39", "r292", "r334" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r416", "r417", "r418", "r420", "r421", "r422", "r423", "r441", "r442", "r480", "r488", "r492" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "auth_ref": [ "r44", "r343", "r386" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription receivable from investors who have been allocated common stock.", "label": "[Common Stock, Share Subscribed but Unissued, Subscriptions Receivable]", "negatedLabel": "Subscription Receivable" } } }, "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r44", "r335" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r44", "r335", "r354", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r44", "r294", "r415" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock - $0.001 par value, 300,000,000 shares Authorized, 241,123,222 and 230,871,034 shares issued and outstanding at June 30, 2023 and December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible notes payable, net of debt discount" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r42", "r73" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Payable" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r69", "r116", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Promissory Note Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r14", "r34", "r182" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest Rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r33", "r37", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Unamortized Debt Discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r33", "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r433" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Unrecognized compensation cost" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r23", "r24" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Per Share Information" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r5", "r89", "r103", "r104", "r105", "r119", "r120", "r121", "r123", "r128", "r130", "r137", "r159", "r160", "r201", "r232", "r233", "r234", "r241", "r242", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r260", "r261", "r262", "r263", "r264", "r265", "r273", "r300", "r301", "r302", "r315", "r379" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ExplorationExpense": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exploration expenses (including prospecting) related to oil and gas producing entities and would be included in operating expenses of that entity. Costs incurred in identifying areas that may warrant examination and in examining specific areas that are considered to have prospects of containing oil and gas reserves, including costs of drilling exploratory wells and exploratory-type stratigraphic test wells. Exploration costs may be incurred both before acquiring the related property (sometimes referred to in part as prospecting costs) and after acquiring the property. Principal types of exploration costs, which include depreciation and applicable operating costs of support equipment and facilities and other costs of exploration activities, are: (i) Costs of topographical, geographical and geophysical studies, rights of access to properties to conduct those studies, and salaries and other expenses of geologists, geophysical crews, and others conducting those studies. Collectively, these are sometimes referred to as geological and geophysical or \"G&G\" costs. (ii) Costs of carrying and retaining undeveloped properties, such as delay rentals, ad valorem taxes on properties, legal costs for title defense, and the maintenance of land and lease records. (iii) Dry hole contributions and bottom hole contributions. (iv) Costs of drilling and equipping exploratory wells. (v) Costs of drilling exploratory-type stratigraphic test wells.", "label": "[Exploration Expense]", "verboseLabel": "Amortization expense" } } }, "localname": "ExplorationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023 (remaining)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r65", "r288" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents, net", "verboseLabel": "Future Amortization Expense" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r4", "r31", "r32" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on settlement of debt", "negatedLabel": "Loss on settlement of debt", "verboseLabel": "Loss on settlement of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r54", "r118", "r140", "r145", "r149", "r151", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r259", "r411", "r451" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r3" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Accrued liabilities - related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r3" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "terseLabel": "Inventory used", "verboseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]", "negatedLabel": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.", "label": "Principal amount converted to convertible note payable" } } }, "localname": "InducedConversionOfConvertibleDebtExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r28", "r284", "r285", "r286", "r288", "r407" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Patents" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r35", "r77", "r106", "r143", "r267", "r364", "r424", "r490" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "[Interest Expense, Other]", "terseLabel": "Interest expense", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r109", "r112", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrues interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r99", "r405", "r415" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory", "verboseLabel": "Total Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r82", "r93", "r98", "r162", "r163", "r164", "r283", "r408" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentIncomeAmortizationOfDiscount": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion of purchase discount on nonoperating securities.", "label": "Debt discount amortization related to OID" } } }, "localname": "InvestmentIncomeAmortizationOfDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r418", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Interest rate" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuances of Securities" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r4" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock for services and compensation" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term Axis" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "verboseLabel": "Litigation" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/Litigation" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023 (Remaining)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r11", "r118", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r245", "r248", "r249", "r259", "r333", "r410", "r426", "r451", "r484", "r485" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r49", "r75", "r296", "r415", "r440", "r448", "r481" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r92", "r118", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r245", "r248", "r249", "r259", "r415", "r451", "r484", "r485" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Civil penalty amount" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status Axis" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation." } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans payable - related parties", "verboseLabel": "Loans payable - related parties" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Litigation Settlement" } } }, "localname": "LossContingencyAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LossContingencyReceivableProceeds": { "auth_ref": [ "r438", "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the collection of receivables related to a loss contingency.", "label": "Subscription receivable" } } }, "localname": "LossContingencyReceivableProceeds", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Advertising and marketing expenses" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Cash flow provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r59", "r60", "r61" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net Cash Used In Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r53", "r61", "r76", "r90", "r101", "r102", "r105", "r118", "r122", "r124", "r125", "r126", "r127", "r129", "r130", "r133", "r140", "r145", "r149", "r151", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r258", "r259", "r298", "r356", "r377", "r378", "r411", "r424", "r451" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net Loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r6", "r74", "r487" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Promissory note payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total Operating Expenses", "verboseLabel": "Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r140", "r145", "r149", "r151", "r411" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r269" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability - current", "verboseLabel": "Short-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r269" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability - long-term", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/LeasesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Total lease payments" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r271", "r414" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Average discount rate - operating lease" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Basis of Preparation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r55", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Operating lease cost (included in general and administrative in the Company's statement of operations)" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r299", "r358", "r395", "r396", "r397" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other." } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Total other income (expenses)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expenses)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r58" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "[Payments to Acquire Intangible Assets]", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r43", "r188" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r43", "r335" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r43", "r188" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r43", "r335", "r354", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r43", "r293", "r415" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r435" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r18" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock", "verboseLabel": "Proceeds from issuance of cost" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r2", "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from issuance of cost" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r18" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r90", "r101", "r102", "r110", "r118", "r122", "r129", "r130", "r140", "r145", "r149", "r151", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r243", "r246", "r247", "r258", "r259", "r290", "r297", "r314", "r356", "r377", "r378", "r411", "r412", "r413", "r425", "r436", "r451" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net (Loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r108", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableWithImputedInterestDiscount": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face amount.", "label": "[Receivable with Imputed Interest, Discount]", "negatedLabel": "Less Imputed Interest" } } }, "localname": "ReceivableWithImputedInterestDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r277", "r278", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction Axis" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r274", "r275", "r276", "r278", "r279", "r311", "r312", "r313", "r361", "r362", "r363", "r383", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r437" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "[Repayments of Debt]", "negatedLabel": "Repayments on loan payable", "verboseLabel": "Monthly payments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r19", "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Note payable amount payment" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/PromissoryNotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r40", "r240", "r486" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r46", "r71", "r295", "r303", "r304", "r310", "r336", "r415" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "[Retained Earnings (Accumulated Deficit)]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r89", "r119", "r120", "r121", "r123", "r128", "r130", "r159", "r160", "r232", "r233", "r234", "r241", "r242", "r250", "r252", "r253", "r255", "r257", "r300", "r302", "r315", "r492" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r359", "r404", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r107", "r118", "r141", "r142", "r144", "r147", "r148", "r152", "r153", "r154", "r158", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r259", "r290", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of lease expense and supplemental cash flow information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r50", "r51", "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).", "label": "Schedule of Restricted Stock Units" } } }, "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r433" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Litigation Settlement [Member]" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SettlementLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.", "label": "Accrued litigation settlement", "verboseLabel": "Accrued litigation settlement" } } }, "localname": "SettlementLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value, units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average grant date fair value, total awards outstanding, ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r203", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r227", "r228", "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r202", "r206", "r225", "r226", "r227", "r228", "r231", "r235", "r236", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price", "verboseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares]", "periodEndLabel": "Number of units total awards outstanding, ending", "periodStartLabel": "Number of units total awards outstanding, beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted average grant date fair value, units cancelled/forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price]", "periodStartLabel": "Weighted average grant date fair value, total awards outstanding, beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type Axis" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r62", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r88", "r95", "r96", "r97", "r118", "r131", "r132", "r134", "r135", "r138", "r139", "r158", "r165", "r167", "r168", "r169", "r172", "r173", "r188", "r189", "r191", "r194", "r200", "r259", "r306", "r307", "r308", "r309", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r335", "r357", "r379", "r398", "r399", "r400", "r401", "r402", "r431", "r439", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r5", "r17", "r89", "r103", "r104", "r105", "r119", "r120", "r121", "r123", "r128", "r130", "r137", "r159", "r160", "r201", "r232", "r233", "r234", "r241", "r242", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r260", "r261", "r262", "r263", "r264", "r265", "r273", "r300", "r301", "r302", "r315", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r119", "r120", "r121", "r137", "r287", "r305", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r359", "r360", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r379", "r419" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statement of Stockholders Equity (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r119", "r120", "r121", "r137", "r287", "r305", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r359", "r360", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r379", "r419" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedBalanceSheetsParenthetical", "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/ConvertibleNotesDetailsNarrative", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative", "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock for services, shares", "terseLabel": "Stock issued during period, shares", "verboseLabel": "Common stock, shares issued for service renderred, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r43", "r44", "r71", "r306", "r379", "r399" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Sale of common stock, shares", "terseLabel": "Common stock shares issued during the period", "verboseLabel": "Stock issued during period, share" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock for services, amount", "terseLabel": "Stock issued during period, value", "verboseLabel": "Common stock, shares issued for service renderred, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative", "http://unitedhealthproductsinc.com/role/LitigationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r43", "r44", "r71", "r315", "r379", "r399", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Sale of common stock, amount", "verboseLabel": "Stock issued during period, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited", "http://unitedhealthproductsinc.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r44", "r47", "r48", "r64", "r337", "r354", "r380", "r381", "r415", "r426", "r440", "r448", "r481", "r492" ], "calculation": { "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total Stockholders' Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets", "http://unitedhealthproductsinc.com/role/CondensedStatementOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r70", "r117", "r187", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r201", "r256", "r382", "r384", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Issuances of Securities" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r266", "r281" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "verboseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r266", "r281" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r266", "r281" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Event" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r280", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock Axis" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/IssuancesOfSecuritiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r78", "r79", "r80", "r155", "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Trade Accounts Receivable and Concentration Risk" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/AccruedLitigationSettlementDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r25", "r26", "r27", "r84", "r85", "r86", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://unitedhealthproductsinc.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481194/470-20-40-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org//840/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 54 0001477932-23-005842-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-005842-xbrl.zip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Ð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end

I, Brian Thom certifies that:

1.	I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023	By:	/s/ Brian Thom
		Brian Thom
		Principal Executive Officer

I, Kristofer Heaton certifies that:

1.	I have reviewed this quarterly report on Form 10-Q of United Health Products, Inc.;

2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	1.	The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and

	2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.